register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00115297 | [
{
"id_field": "org_study_id",
"id_value": [
"192"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HL080073"
]
}
] | https://clinicaltrials.gov/study/NCT00115297 | Montelukast for Early Life Wheezing | This study will determine the effects of montelukast on the duration of wheezing in children 12 months to 3 years of age who visit a physician for care of a wheezing illness. Only patients from the Ankara area of Hacettepe University Medical Center in Turkey will be included in this study. | Effects of Montelukast on Early Life Wheezing | [
{
"description": "Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.",
"name": "Montelukast",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "... | [
{
"design_group_description": "Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.",
"design_group_title": "Montelukast",
"design_group_type": "Experimental",
"design_group_type_normalized_id": ... | [
"Lung Diseases",
"Asthma"
] | [
"University of Massachusetts"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "孟鲁司特钠",
"lang": "CN"
},
{
"name": "Montelukast sodium",
"lang": "EN"
},
{
"name": "モンテルカストナトリウム",
"lang": "JP"
}
]
] | null |
NCT03962283 | [
{
"id_field": "org_study_id",
"id_value": [
"MISO RF"
]
}
] | https://clinicaltrials.gov/study/NCT03962283 | Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users | Background: Investigators have previously shown that misoprostol can heal small bowel ulcers in aspirin users with small bowel bleeding. However, the rate of small-bowel mucosal healing was low with use of misoprostol alone. There is evidence to suggest that bacteria contribute to the development aspirin-induced ulcers... | Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding: A Double Blind Randomized Trial | [
{
"description": "Rifaximin 200mcg four times daily",
"name": "Rifaximin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo Rifaximin four times daily",
"name": "Placebo oral tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b5... | [
{
"design_group_description": "ASA daily + misoprostol + Rifaximin (Rifaximin group)",
"design_group_title": "Rifaximin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description":... | [
"Small Bowel Disease",
"Rifaximin"
] | [
"The Chinese University of Hong Kong"
] | [
"Beijing Friendship Hospital"
] | [
[
{
"name": "利福昔明",
"lang": "CN"
},
{
"name": "Rifaximin",
"lang": "EN"
},
{
"name": "リファキシミン",
"lang": "JP"
}
]
] | null |
NCT05660746 | [
{
"id_field": "org_study_id",
"id_value": [
"2022-0071"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DK132408-01"
]
},
{
"id_field": "acronym",
"id_value": [
"REMODEL-CD"
]
}
] | https://clinicaltrials.gov/study/NCT05660746 | Precise Infliximab Exposure and Pharmacodynamic Control | Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment.<br/>The main reason for thi... | Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease | [
{
"description": "The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.",
"name": "RoadMAB",
"normalized_type": "63bce838d71c4229808b289e8cf3172d",
"type": "Device"
},
{
"descript... | [
{
"design_group_description": "Induction Phase: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance Phase : 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.",
"design_group_title": "Conventional dosing",
"design_group_type": "Active Comparator",
... | [
"Crohn Disease"
] | [
"Cincinnati Children's Hospital Medical Center"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases",
"Janssen Scientific Affairs LLC"
] | [
[
{
"name": "英夫利西单抗",
"lang": "CN"
},
{
"name": "Infliximab",
"lang": "EN"
},
{
"name": "インフリキシマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "REMODEL-CD"
}
] |
NCT00310791 | [
{
"id_field": "org_study_id",
"id_value": [
"Anorexia04"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HD043869"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT01343771"
]
}
] | https://clinicaltrials.gov/study/NCT00310791 | Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa | This study seeks to gain new information on why young women with anorexia nervosa are predisposed to early bone loss and osteoporosis. Through a randomized treatment trial in which participants will receive either combined therapy with the adrenal hormone, dehydroepiandrosterone (DHEA) and estrogen replacement therapy ... | Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa | [
{
"description": "Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)",
"name": "Hormone replacement therapy (estrogen/progestin)",
"normalized_type": "3d1aa88261d64c0384137... | [
{
"design_group_description": "Placebo (sugar pill); identical to treatment medication capsule",
"design_group_title": "Sugar Pill",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_d... | [
"Anorexia Nervosa"
] | [
"The Children's Hospital Corp."
] | [
"Defense Language Institute Foreign Language Center",
"National Institute of Child Health & Human Development"
] | [
[
{
"name": "普拉睾酮",
"lang": "CN"
},
{
"name": "Prasterone",
"lang": "EN"
}
]
] | null |
NCT00781898 | [
{
"id_field": "org_study_id",
"id_value": [
"808422"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA024553"
]
}
] | https://clinicaltrials.gov/study/NCT00781898 | Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site | The aim of this project is to conduct a multi-site effectiveness study to determine whether the addition of a monthly injection of depot naltrexone to treatment as usual (TAU) will significantly improve outcome in parolees and probationers with a history of opioid addiction compared to TAU alone. Participants will be r... | Prevention of Relapse to Opioid Addiction Using Depot Naltrexone | [
{
"description": "Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.",
"name": "Depot naltrexone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Treatment as Usual (TAU) community treatment provid... | [
{
"design_group_title": "Depot Naltrexone",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intr... | [
"Opiate Addiction"
] | [
"University of Pennsylvania"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "盐酸纳曲酮",
"lang": "CN"
},
{
"name": "Naltrexone Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT01936844 | [
{
"id_field": "org_study_id",
"id_value": [
"VCU HM15347"
]
}
] | https://clinicaltrials.gov/study/NCT01936844 | Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF) | Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protein over 14 days. | Interleukin-1 Blockade in Acute Decompensated Heart Failure | [
{
"description": "Anakinra 100 mg daily twice daily for days 1, 2, and 3",
"name": "Anakinra (high dose)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Anakinra 100 mg daily for days 4-14",
"name": "Anakinra (standard dose)",
"normalized_... | [
{
"design_group_description": "Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14",
"design_group_title": "Anakinra (short)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{... | [
"Heart Failure"
] | [
"Virginia Commonwealth University"
] | [
"American Heart Association, Inc."
] | [
[
{
"name": "安纳白介素",
"lang": "CN"
},
{
"name": "Anakinra (Amgen)",
"lang": "EN"
}
]
] | null |
NCT05463484 | [
{
"id_field": "org_study_id",
"id_value": [
"02-2021"
]
}
] | https://clinicaltrials.gov/study/NCT05463484 | Effects of a Composition on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases and Inflammation in Oral Dysbiosis | Dysbiosis is a condition in which the normal function of an ecological net is altered. In dysbiosis a state of inflammation, a loss of hydration, a change in pH, a loss of the barrier function are all allies of key pathogens that initiate invasion and cytokine and pro-inflammatory mediators release that target other ti... | Effects of a Composition Delivered Via Toothpaste on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases, and Inflammation in Patients With Oral Dysbiosis: A Controlled, Randomized, Double-blind Study. Part of Stop Dysbiosis Project | [
{
"description": "Fluoridated toothpaste with Saliactive®.",
"name": "Test composition Saliactive® (olive product, betaine and xylitol)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Saliactive®"
],
"type": "Drug"
},
{
"description": "Fluoridated toot... | [
{
"design_group_description": "Toothpaste including an olive product, betaine and xylitol (Saliactive®).",
"design_group_title": "Test product",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interven... | [
"Oral Dysbiosis"
] | [
"Mucosa Innovations, S.L."
] | [
"University of Granada"
] | [
[
{
"name": "丙酸氟替卡松/昔萘酸沙美特罗",
"lang": "CN"
},
{
"name": "Fluticasone propionate/Salmeterol xinafoate",
"lang": "EN"
},
{
"name": "サルメテロールキシナホ酸塩/フルチカゾンプロピオン酸エステル",
"lang": "JP"
}
]
] | null |
NCT00490854 | [
{
"id_field": "org_study_id",
"id_value": [
"10513"
]
},
{
"id_field": "secondary_id",
"id_value": [
"H7U-JE-IDBF"
]
}
] | https://clinicaltrials.gov/study/NCT00490854 | A Study for Patients With Type 2 Diabetes Mellitus | The purpose of the study is to compare the human insulin inhalation powder plus oral anti-hyperglycemic medication with injected insulin (neutral protamine hegedom insulin) plus oral anti-hyperglycemic medication on lowering the blood sugar level. | A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Once-Daily NPH in Insulin-Naïve Patients With Type 2 Diabetes Mellitus on Oral Agents | [
{
"description": "patient specific, inhaled, at meals, 76 weeks",
"name": "Human Insulin Inhalation Powder",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LY 041001"
],
"type": "Drug"
},
{
"description": "patient specific dose, injected, daily, 76 week... | [
{
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "patient specific dose, injected, daily, 76 weeks",
"intervention_name": "Neutral protamine h... | [
"Diabetes Mellitus, Type 2"
] | [
"Eli Lilly & Co."
] | [
"Alkermes, Inc."
] | [
[
{
"name": "人胰岛素（诺和诺德）",
"lang": "CN"
},
{
"name": "Insulin human (rDNA origin, Novo Nordisk)",
"lang": "EN"
},
{
"name": "インスリン ヒト（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00713167 | [
{
"id_field": "org_study_id",
"id_value": [
"SBMU 87-01-106-5694"
]
},
{
"id_field": "acronym",
"id_value": [
"GSE"
]
}
] | https://clinicaltrials.gov/study/NCT00713167 | The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL) | Antioxidants are potent scavengers of free radicals and serve as inhibitors of neoplastic processes. A large number of synthetic and natural antioxidants are known to induce beneficial effects on human health and disease prevention. Cardioprotective ability of grape seed extract polyphenols (GSEP) was studied in animal... | Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Grape Seed Extract in Treating Patients With Mild Hyperlipidemia | [
{
"description": "Drug {Each Containing: Grape Seed Extract100 mg +...}<br/>1 capsule twice daily for 2 months",
"name": "Grape Seed Extract (Vitagrape)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Iran Ministry of Health Registration Number: 5/92/43198",
"Vi... | [
{
"design_group_description": "Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules",
"design_group_title": "Grape Seed Extract",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Hyperlipidemia"
] | [
"Shahid Beheshti University of Medical Sciences"
] | [
"University of Tabriz"
] | [
[
{
"name": "葡萄籽提取物",
"lang": "CN"
},
{
"name": "Grape Seed Extract",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GSE"
}
] |
NCT06424834 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB-75085"
]
},
{
"id_domain": "American Heart Association",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"24POST1189688"
]
},
{
"id_field": "acronym",
"id_value": [
"... | https://clinicaltrials.gov/study/NCT06424834 | Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries | The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.<br/>Participants will be tr... | A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study | [
{
"description": "Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.",
"name": "Amlodipine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Katerzia",
"Norliqva",
"Norvasc"
],
"type": "Drug"... | [
{
"design_group_description": "1. Epicardial or microvascular coronary spasm: Amlodipine 2.5mg initial dose, 10mg max dose<br/>2. Coronary microvascular dysfunction: Nebivolol 5mg initial dose, 20mg max dose<br/>3. Myocardial Bridge: Nebivolol 5mg initial dose, 20mg max dose<br/>4. Mixed epicardial/microvascula... | [
"Angina Pectoris",
"Microvascular Angina",
"Vasospastic Angina",
"Myocardial Bridge of Coronary Artery"
] | [
"Stanford University"
] | [
"American Heart Association, Inc."
] | [
[
{
"name": "盐酸奈必洛尔",
"lang": "CN"
},
{
"name": "Nebivolol hydrochloride",
"lang": "EN"
}
],
[
{
"name": "苯磺酸氨氯地平",
"lang": "CN"
},
{
"name": "Amlodipine Besylate",
"lang": "EN"
},
{
"name": "アムロジピンベシル酸塩",
"lang": "J... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MVP-ANOCA"
}
] |
NCT01306331 | [
{
"id_field": "org_study_id",
"id_value": [
"AMP001"
]
}
] | https://clinicaltrials.gov/study/NCT01306331 | Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel | This is a research study of a new experimental vaginal gel that helps in vaginal pH regulation and results in immobilization of spermatozoa by maintaining the normally low vaginal pH, even in the presence of semen. This vaginal gel is called Phexxi™ (previously known as Amphora) and was compared to a commercially avail... | A Multicenter, Open-Label, Randomized Study of the Contraceptive Efficacy and Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel | [
{
"description": "• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.",
"name": "Conceptrol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "• Amphora™ gel, which will be delivered in 5 ... | [
{
"design_group_description": "100 mg (4% concentration) of nonoxynol-9 in 2.5 mL volume of gel",
"design_group_title": "Conceptrol",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_d... | [
"Contraception"
] | [
"Evofem, Inc."
] | [
"Health Decisions, Inc."
] | [
[
{
"name": "Amphora",
"lang": "EN"
}
]
] | null |
NCT04650087 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00107078"
]
}
] | https://clinicaltrials.gov/study/NCT04650087 | COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis | A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge | COVID-19 Post-hospital Thrombosis Prevention Trial: An Adaptive, Multicenter, Prospective, Randomized Platform Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients With COVID-19 Following Hospital Discharge | [
{
"description": "Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur fr... | [
{
"design_group_description": "Drug: Apixaban 2.5 MG Participants will be given study medication at the time of discharge from the hospital. Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening, for 30 days. Participants will be contacted (electronic or telephone) 2 da... | [
"Covid19"
] | [
"Duke University"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "阿哌沙班",
"lang": "CN"
},
{
"name": "Apixaban",
"lang": "EN"
},
{
"name": "アピキサバン",
"lang": "JP"
}
]
] | null |
NCT00859898 | [
{
"id_field": "org_study_id",
"id_value": [
"MB102-034"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Eudract #: 2008-007548-33"
]
}
] | https://clinicaltrials.gov/study/NCT00859898 | Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes | The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety... | A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inade... | [
{
"description": "Tablets, Oral, 10 mg, once daily, 24 weeks",
"name": "Dapagliflozin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Farxiga™"
],
"type": "Drug"
},
{
"description": "Tablets, Oral, up to 2000 mg, once daily, 24 weeks",
"name": "Met... | [
{
"design_group_description": "Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks<br/>Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks",
"design_group_title": "Dapagliflozin + Metformin XR",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3... | [
"Type 2 Diabetes Mellitus"
] | [
"AstraZeneca PLC"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "达格列净",
"lang": "CN"
},
{
"name": "Dapagliflozin",
"lang": "EN"
},
{
"name": "ダパグリフロジンプロピレングリコール水和物",
"lang": "JP"
}
],
[
{
"name": "二甲双胍",
"lang": "CN"
},
{
"name": "Metformin",
"lang": "EN"
}
]
] | null |
NCT06819878 | [
{
"id_field": "org_study_id",
"id_value": [
"GA45331"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2024-513053-69-00"
]
},
{
"id_field": "acronym",
"id_value": [
"SIBERITE-1"
]
}
] | https://clinicaltrials.gov/study/NCT06819878 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD). | A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease | [
{
"description": "Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.",
"name": "Afimkibart",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"PF-06480605",
"RG6631",
"RO7790121",
"RVT-3101"
],
"type"... | [
{
"design_group_description": "Participants will receive afimkibart intravenously (IV) followed by afimkibart subcutaneous (SC) injection.",
"design_group_title": "Arm 1: Afimkibart",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"int... | [
"Moderately to Severely Active Crohns Disease"
] | [
"Hoffmann-La Roche Ltd."
] | [
"Chugai Pharmaceutical Co., Ltd."
] | [
[
{
"name": "Afimkibart",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SIBERITE-1"
}
] |
NCT05985798 | [
{
"id_field": "org_study_id",
"id_value": [
"MIIR-13"
]
}
] | https://clinicaltrials.gov/study/NCT05985798 | Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC | This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus TACE (Sin-Bev-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced stage hepatocellular carcinoma (HCC). | Sintilimab, Bevacizumab Plus TACE Versus Lenvatinib Plus TACE for Advanced Stage Hepatocellular Carcinoma: A Randomized Controlled Trial | [
{
"description": "Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.",
"name": "Sin-Bev-TACE",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "Sintilimab, bevacizumab plus TACE",
"design_group_title": "Sin-Bev-TACE",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Sintilimab (200mg I.... | [
"Hepatocellular Carcinoma Non-resectable"
] | [
"Second Affiliated Hospital of Guangzhou Medical University"
] | [
"Affiliated Tumor Hospital of Guangzhou Medical University",
"Zhongshan People's Hospital"
] | [
[
{
"name": "信迪利单抗",
"lang": "CN"
},
{
"name": "Sintilimab",
"lang": "EN"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
"name": "ベバシズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00021281 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000068766"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCLA-001003701"
]
},
{
"id_field": "secondary_id",
"id_value": [
"SUGEN-SU5416.035"
]
},
{
"id_field": "secondary_id",
"id_value": [... | https://clinicaltrials.gov/study/NCT00021281 | Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether combination chemotherapy will be more effective with or without SU5416 in treating metastatic... | A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer | [
{
"name": "FOLFIRI regimen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "fluorouracil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "irinotecan hydrochloride",
... | null | [
"Colorectal Cancer"
] | [
"Jonsson Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "司马沙尼",
"lang": "CN"
},
{
"name": "Semaxanib",
"lang": "EN"
}
],
[
{
"name": "亚叶酸钙",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
{
"name": "ホリナートカルシウム",
"lang": "JP"
}
],
[
... | null |
NCT04861259 | [
{
"id_field": "org_study_id",
"id_value": [
"BO42353"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2020-002475-35"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2023-505089-27... | https://clinicaltrials.gov/study/NCT04861259 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS. | A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) | [
{
"description": "Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be adm... | [
{
"design_group_description": "Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another Complement Component 5 (C5) inhibitor and [3] C5 Single Nu... | [
"Atypical Hemolytic Uremic Syndrome"
] | [
"Hoffmann-La Roche, Inc."
] | [
"Chugai Pharmaceutical Co., Ltd."
] | [
[
{
"name": "可伐利单抗",
"lang": "CN"
},
{
"name": "Crovalimab",
"lang": "EN"
},
{
"name": "クロバリマブ（遺伝子組換え）（JAN）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "COMMUTE-a"
},
{
"identifier_source": [
{
"code": "a8528ea52a80244a2a50deae8532a892",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
... |
NCT01124929 | [
{
"id_field": "org_study_id",
"id_value": [
"Abdominal TB_RCT (RNTCP-DOTS)"
]
},
{
"id_field": "acronym",
"id_value": [
"RNTCP-DOTS"
]
}
] | https://clinicaltrials.gov/study/NCT01124929 | Treatment Duration for Abdominal Tuberculosis | Most of the guidelines on the treatment of tuberculosis suggest that 6 months treatment is sufficient for extrapulmonary tuberculosis except for bone tuberculosis and tubercular meningitis. Despite these recommendations, most physicians treating abdominal tuberculosis use antituberculous therapy for 9 months, sometimes... | A Multi-centric Study on Treatment of Abdominal Tuberculosis (Intestinal or Peritoneal): A Randomized Controlled Trial to Compare the 6 Months of Cat I Treatment With 9 Months of Cat I Treatment (Extension for 3 Months) in Abdominal Tuberculosis Under the Revised National Tuberculosis Control Program | [
{
"description": "2H3R3Z3 E3 + 4H3R3",
"name": "RNTCP Category I treatment for 6 months",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "2H3R3Z3 E3 + 7H3R3",
"name": "RNTCP Category I treatment for 9months",
"normalized_type": "3d1aa88261d6... | [
{
"design_group_description": "Anti-tuberculosis drugs",
"design_group_title": "Arm 1: Category I treatment for 6 months",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description"... | [
"Tuberculosis"
] | [
"All India Institute of Medical Sciences"
] | [
"Sanjay Gandhi Post Graduate Institute of Medical Sciences",
"Christian Medical College & Hospital"
] | [
[
{
"name": "乙胺吡嗪利福异烟",
"lang": "CN"
},
{
"name": "Ethambutol Hydrochloride/Isoniazid/Pyrazinamide/Rifampicin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RNTCP-DOTS"
}
] |
NCT05736861 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00107921_A"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"3U24TR001608-05W1"
]
}
] | https://clinicaltrials.gov/study/NCT05736861 | ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400) | The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may... | ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications | [
{
"description": "Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with \"123\" over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.",
... | [
{
"design_group_description": "Ivermectin - 7-mg tablets<br/>Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg.",
"design_group_title": "Arm A - Ivermectin 400",
"design_group_type": "Expe... | [
"Covid19"
] | [
"Duke University"
] | [
"Vanderbilt University Medical Center",
"National Center for Advancing Translational Sciences"
] | [
[
{
"name": "伊维菌素",
"lang": "CN"
},
{
"name": "Ivermectin",
"lang": "EN"
},
{
"name": "イベルメクチン",
"lang": "JP"
}
]
] | null |
NCT02419664 | [
{
"id_field": "org_study_id",
"id_value": [
"Ga-PET version 8 (141017)"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2010-020482-24"
]
}
] | https://clinicaltrials.gov/study/NCT02419664 | Ga-68-DOTATOC -PET in the Management of Pituitary Tumours | Title: Gallium (GA) -68-DOTATOC -PET (positron emission tomography) in the management of pituitary tumours Medical product: Ga-68-DOTATOC in PET/computer tomography (CT) Route of administration: Intravenously Diseases of interest: Pituitary tumours Aim: To study the detection of pituitary tumours with Ga-68-DOTATOC -PE... | Ga-68-DOTATOC -PET in the Management of Pituitary Tumours | [
{
"description": "The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT",
"name": "Gallium-68 DOTATOC PET",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ga-PET"
],
"type": "Drug"
}
] | [
{
"design_group_description": "To give Ga-68 DOTATOC in pituitary patients doing PET/CT<br/>They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease.",
"design_group_title": "Ga-68 DOTATOC PET in pituitary adenomas",
"design_group_type": "Experimental",
... | [
"Pituitary Tumours"
] | [
"University of Gothenburg"
] | [
"Sahlgrenska Universitetssjukhuset",
"University of Uppsala"
] | [
[
{
"name": "镓[68Ga]伊索曲肽",
"lang": "CN"
},
{
"name": "68Ga-Edotreotide",
"lang": "EN"
}
]
] | null |
NCT02385097 | [
{
"id_field": "org_study_id",
"id_value": [
"CHL.2/01-2014/M"
]
}
] | https://clinicaltrials.gov/study/NCT02385097 | Chloroprocaine 2% vs Ropivacaine 0.75% in Ultrasound-guided Axillary Nerve Block | The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min. | A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery | [
{
"description": "Single Administration (20mL) by Axillary Nerve Route",
"name": "Chloroprocaine HCl 2%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ampres"
],
"type": "Drug"
},
{
"description": "Single Administration (20mL) by Axillary Nerve Route"... | [
{
"design_group_description": "Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL",
"design_group_title": "Chloroprocaine HCl 2% (20 mg/mL)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"i... | [
"Axillary Nerve Block"
] | [
"Sintetica SA"
] | [
"Cross SA"
] | [
[
{
"name": "盐酸氯普鲁卡因",
"lang": "CN"
},
{
"name": "Chloroprocaine Hydrochloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "4e8330433a422534a505a252a8aa4388",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "52580e52d9290852d90aa2532285a43e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "not... |
NCT00441584 | [
{
"id_field": "org_study_id",
"id_value": [
"P03833"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ESPECIAL"
]
}
] | https://clinicaltrials.gov/study/NCT00441584 | The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) | This is an uncontrolled, non-randomized, open-label, multinational study designed to evaluate the efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C. The study is designed to determine the proportion of chronic hepatitis C genotype 1 subjects who did not respond to previous treatment wit... | Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys | [
{
"description": "Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks",
"name": "PegIntron (peginterferon alfa-2b)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"S... | [
{
"design_group_description": "PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks",
"design_group_title": "PegIntron plus Rebetol",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Hepatitis C, Chronic"
] | [
"Merck Sharp & Dohme Corp."
] | [
"Integrated Therapeutics Group, Inc."
] | [
[
{
"name": "聚乙二醇干扰素α-2b注射(Merck & Co)",
"lang": "CN"
},
{
"name": "Peginterferon alfa-2b(Merck & Co)",
"lang": "EN"
}
],
[
{
"name": "利巴韦林",
"lang": "CN"
},
{
"name": "Ribavirin",
"lang": "EN"
},
{
"name": "リバビリン",
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2d32a29d80982a85deaa892d398549e5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "P03833"
}
] |
NCT06258811 | [
{
"id_field": "org_study_id",
"id_value": [
"TopHill"
]
}
] | https://clinicaltrials.gov/study/NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally advanced and resectable oral squamous cell carcinoma. | Neoadjuvant Immunochemotherapy With Tislelizumab, Albumin Paclitaxel and Cisplatin Followed by Standard Therapy Versus Standard Therapy for Locally Advanced Oral Squamous Cell Carcinoma, a Multicenter Randomized Phase 3 Trial | [
{
"description": "Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks ... | [
{
"design_group_description": "Neoadjuvant immunochemotherapy (albumin paclitaxel+cisplatin+tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation + tislelizumab maitainance)",
"design_group_title": "Experimental arm",
"design_group_type": "Experimental",
"design_group_type_nor... | [
"Oral Squamous Cell Carcinoma",
"Locally Advanced Head and Neck Carcinoma"
] | [
"Shanghai Huashan Hospital"
] | [
"Fujian Medical University",
"Central South University",
"Sun Yat-Sen University",
"Fudan University"
] | [
[
{
"name": "替雷利珠单抗",
"lang": "CN"
},
{
"name": "Tislelizumab",
"lang": "EN"
},
{
"name": "チスレリズマブ（遺伝子組換え）（JAN）",
"lang": "JP"
}
]
] | null |
NCT04192266 | [
{
"id_field": "org_study_id",
"id_value": [
"HSC-MS-23-0497"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R33MH111907"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT03371654"
]
},
{
"id_field": "... | https://clinicaltrials.gov/study/NCT04192266 | Estrogen and Fear in PTSD | The purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study across UTHealth Houston and UPenn (40 su... | A Randomized, Double-blind Placebo-controlled Multi-center Study of Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy | [
{
"description": "2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)",
"name": "Estradiol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Estrace"
],
"type": "Drug"
},
{
"... | [
{
"design_group_description": "A single 2mg dose of estradiol (a form of estrogen) will be taken at home by the study participant 5-6 hours before each of 5 prolonged exposure (PE) therapy treatment sessions (sessions 2 to 6). PE therapy is a validated treatment for PTSD.",
"design_group_title": "Prolonged ... | [
"PTSD"
] | [
"The University of Texas Health Science Center at Houston"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "戊酸雌二醇",
"lang": "CN"
},
{
"name": "Estradiol Valerate",
"lang": "EN"
},
{
"name": "エストラジオール吉草酸エステル",
"lang": "JP"
}
]
] | null |
NCT02060903 | [
{
"id_field": "org_study_id",
"id_value": [
"Ha03-001"
]
}
] | https://clinicaltrials.gov/study/NCT02060903 | A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation | The purpose of the study was to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the scalp and hair for 10 minutes at home. | A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation | [
{
"description": "Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.",
"name": "Abametapir Lotion 0.74% w/w",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Abametapir 0.74%"
],
"type": "Drug"
},
{
... | [
{
"design_group_description": "Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.",
"design_group_title": "Abametapir Lotion 0.74% w/w",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e... | [
"Head Lice Infestation"
] | [
"Dr. Reddy's Laboratories Ltd. (Russia)"
] | [
"Accelovance, Inc.",
"Syneos Health, Inc."
] | [
[
{
"name": "Abametapir",
"lang": "EN"
}
]
] | null |
NCT01324934 | [
{
"id_field": "org_study_id",
"id_value": [
"AP-AS-24-ES"
]
},
{
"id_field": "acronym",
"id_value": [
"IBERICA"
]
}
] | https://clinicaltrials.gov/study/NCT01324934 | Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids | The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a treatment consisting of CellCept® or Myf... | Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Im... | [
{
"description": "Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.<br/>(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of AT... | [
{
"design_group_description": "immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic",
"design_group_title": "Study Group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"in... | [
"Renal Transplant Rejection"
] | [
"Neovii Biotech GmbH"
] | [
"Eurotrials Brasil Consultores Científicos Ltda.",
"PsyConsult VOF"
] | [
[
{
"name": "抗人T细胞兔免疫球蛋白",
"lang": "CN"
},
{
"name": "Anti-human T Lymphocyte Rabbit Immunoglobulin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "IBERICA"
}
] |
NCT03840421 | [
{
"id_field": "org_study_id",
"id_value": [
"2018-FXY-140"
]
}
] | https://clinicaltrials.gov/study/NCT03840421 | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal carcinoma( NPC ) patients. | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma：a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial | [
{
"description": "Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.",
"name": "gemcitabine and cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"gemcitabine and cisplatin (... | [
{
"design_group_description": "Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.",
"design_group_title": "gemcit... | [
"Nasopharyngeal Carcinoma",
"Nasopharyngeal Neoplasms",
"Nasopharyngeal Diseases",
"Head and Neck Neoplasm"
] | [
"Sun Yat-Sen University"
] | [
"Guangdong General Hospital",
"the First Affiliated Hospital of Sun Yat-Sen University"
] | [
[
{
"name": "吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine",
"lang": "EN"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
]
] | null |
NCT03155997 | [
{
"id_field": "org_study_id",
"id_value": [
"16338"
]
},
{
"id_domain": "Eli Lilly and Company",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"I3Y-MC-JPCF"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_... | https://clinicaltrials.gov/study/NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer. | A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | [
{
"description": "Administered orally.",
"name": "Abemaciclib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LY2835219"
],
"type": "Drug"
},
{
"description": "Administered according to label instructions.",
"name": "Standard Adjuvant Endocrine The... | [
{
"design_group_description": "Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) stan... | [
"Breast Cancer"
] | [
"Eli Lilly & Co."
] | [
"NSABP Foundation, Inc."
] | [
[
{
"name": "阿贝西利",
"lang": "CN"
},
{
"name": "Abemaciclib",
"lang": "EN"
},
{
"name": "アベマシクリブ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "0e2ae0325842a03ed85238058d220242",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "20a02229aa022e52ee282a5392a88845",
"s... |
NCT02593773 | [
{
"id_field": "org_study_id",
"id_value": [
"HZNP-ACT-302"
]
},
{
"id_field": "acronym",
"id_value": [
"STEADFAST"
]
}
] | https://clinicaltrials.gov/study/NCT02593773 | Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study | The purpose of this phase 3 multi-center, open-label extension study is to evaluate the long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia. | Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia | [
{
"description": "The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in... | [
{
"design_group_description": "Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.",
"design_group_title": "interferon γ-1b",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention... | [
"Friedreich's Ataxia"
] | [
"Amgen, Inc."
] | [
"The Friedreich's Ataxia Research Alliance"
] | [
[
{
"name": "干扰素γ-1b",
"lang": "CN"
},
{
"name": "Interferon gamma-1b",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8d20a95a4042593e89dde0a22ea5d532",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "STEADFAST"
}
] |
NCT00001127 | [
{
"id_field": "org_study_id",
"id_value": [
"DMID 99-021"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AV012"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AV012;DMID 99-021"
]
}
] | https://clinicaltrials.gov/study/NCT00001127 | Study of a Flu Vaccine in Children | This study tests the safety and effectiveness of a flu vaccine in school children.<br/>School children are usually the first members of a community to come down with the flu, and they often give the flu to their younger siblings, parents, and grandparents. It is hoped that giving school children a flu vaccine can help ... | Study of the Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in a Community-Based, Non-Randomized, Open-Label Trial in Children to Assess Safety and Herd Immunity for the Control of Epidemic Influenza | [
{
"name": "Influenza virus vaccine (CAIV-T)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
}
] | null | [
"Influenza"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"Aviron LLC"
] | [
[
{
"name": "Influenza virus vaccine(Protein Sciences Corp.)",
"lang": "EN"
}
]
] | null |
NCT00336167 | [
{
"id_field": "org_study_id",
"id_value": [
"05-05-19"
]
}
] | https://clinicaltrials.gov/study/NCT00336167 | Bezafibrate Trial in CPT2 Deficiency | The purpose of this study is to determine whether bezafibrate is effective in the treatment of the muscular adult form of carnitine palmitoyltransferase 2 deficiency | Clinical Trial on the Effect of Bezafibrate in the Muscular Form of Carnitine Palmitoyltransferase 2 Deficiency | [
{
"name": "bezafibrate (drug)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Carnitine Palmitoyl Transferase 2 Deficiency"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
"Institut National de la Santé et de la Recherche Médicale"
] | [
[
{
"name": "苯扎贝特",
"lang": "CN"
},
{
"name": "Bezafibrate",
"lang": "EN"
},
{
"name": "ベザフィブラート",
"lang": "JP"
}
]
] | null |
NCT00287079 | [
{
"id_field": "org_study_id",
"id_value": [
"IMP 26222"
]
},
{
"id_field": "acronym",
"id_value": [
"CIS-ON"
]
}
] | https://clinicaltrials.gov/study/NCT00287079 | A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome | The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc) interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to Clinically Definite Multiple Sclerosis (CDMS) - as defined by the occurrence of a second exacerbation - over 96 weeks in subjects that pres... | A Prospective, Open Label, Multi-centre Study Exploring the Use of Subcutaneous (sc) 44 Microgram Interferon (IFN) Beta - 1a (Rebif®) Once a Week (qw) in Subjects With Clinically Isolated Syndrome (CIS) | [
{
"description": "44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks",
"name": "Rebif®",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "No treatment for 96 weeks",
"name": "No Treatment",
"normalized_type": "ffd65a2d86954c7285f... | [
{
"design_group_title": "Rebif®",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks",
"intervention_name": ... | [
"Clinically Isolated Syndrome"
] | [
"Merck KGaA"
] | [
"EMD Serono Canada Inc."
] | [
[
{
"name": "干扰素β-1a(Merck Serono SA)",
"lang": "CN"
},
{
"name": "INTERFERON BETA-1A(Merck Serono SA)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "ae852ede4aee4d5ea22ee58a8a8a3a28",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CIS-ON"
}
] |
NCT00850343 | [
{
"id_field": "org_study_id",
"id_value": [
"CDP870-275-08-004"
]
},
{
"id_field": "secondary_id",
"id_value": [
"JapicCTI-090701"
]
}
] | https://clinicaltrials.gov/study/NCT00850343 | Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients | The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol when administered without coadministration of methotrexate over the long term in Japanese RA patients who transferred from Study 275-08-003 (NCT00791921), and to evaluate the effects of different dosing regimens on the safety and... | A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered Without Coadministration of Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-003) | [
{
"description": "Subcutaneous (SC) injection",
"name": "Certolizumab pegol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CDP870",
"Cimzia"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.",
"design_group_title": "Certolizumab pegol 200 mg",
"design_group_type": "Experimenta... | [
"Rheumatoid Arthritis"
] | [
"Astellas Pharma, Inc."
] | [
"UCB Japan Co. Ltd."
] | [
[
{
"name": "培塞利珠单抗",
"lang": "CN"
},
{
"name": "Certolizumab Pegol",
"lang": "EN"
},
{
"name": "セルトリズマブ ペゴル（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00043537 | [
{
"id_field": "org_study_id",
"id_value": [
"R01MH053703"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01MH053703"
]
}
] | https://clinicaltrials.gov/study/NCT00043537 | Treatment of Childhood Social Phobia | This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents. | Treatment of Childhood Social Phobia | [
{
"name": "Social Effectiveness Therapy for Children (SET-C)",
"normalized_type": "f9cf04e7d3da41f2ae5e11bc777942f7",
"type": "Behavioral"
},
{
"name": "Fluoxetine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Pill Placebo",
"normalized... | [
{
"design_group_description": "Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy",
"design_group_title": "Social Effectiveness Therapy for Children",
"design_group_type": "Experimental",
"design_group_type_normalized_id": ... | [
"Social Phobia"
] | [
"University of Central Florida"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "盐酸氟西汀",
"lang": "CN"
},
{
"name": "Fluoxetine Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT01625182 | [
{
"id_field": "org_study_id",
"id_value": [
"CFTY720I2201"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2011-005280-24"
]
}
] | https://clinicaltrials.gov/study/NCT01625182 | Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. | The study was designed to evaluate the efficacy and safety of fingolimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo. | A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | [
{
"description": "Fingolimod 0.5 mg capsules",
"name": "Fingolimod",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Matching placebo capsules",
"name": "Placebo Comparator",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type":... | [
{
"design_group_description": "Participants received Fingolimod 0.5 mg orally once daily.",
"design_group_title": "Fingolimod (FTY720)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_des... | [
"Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
] | [
"Novartis Pharmaceuticals Corp."
] | [
"Tanabe Pharma Corp."
] | [
[
{
"name": "盐酸芬戈莫德",
"lang": "CN"
},
{
"name": "Fingolimod Hydrochloride",
"lang": "EN"
},
{
"name": "フィンゴリモド塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "330908d588aee8a5e94ea0d980e02932",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "885282225202824a94438a955d823eed",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "FOR... |
NCT04303026 | [
{
"id_field": "org_study_id",
"id_value": [
"2018030"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-000757-31"
]
}
] | https://clinicaltrials.gov/study/NCT04303026 | The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip | Hip Osteoarthritis (OA) is one of the most common diseases affecting the ageing population. No specific and safe treatment slowing the development of hip OA as reflected in reduced joint space narrowing has been developed so far. Implantation of hip prosthesis has been a great success, but is expensive and puts a great... | A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis | [
{
"description": "5mg IV infusion",
"name": "Zoledronic Acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Active Treatment"
],
"type": "Drug"
},
{
"description": "Placebo Group. Saline 0.9% 100 ml infusion",
"name": "Saline 0.9%",
"normalize... | [
{
"design_group_description": "Participants receiving active treatment with two infusions of Zoledronic Acid 5 mg with 3 months interval mixed in 100 ml 0.9% saline",
"design_group_title": "Treatment Group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a... | [
"Osteoarthritis, Hip"
] | [
"Martina Hansens Hospital AS"
] | [
"University of Oslo"
] | [
[
{
"name": "唑来膦酸",
"lang": "CN"
},
{
"name": "Zoledronic Acid",
"lang": "EN"
},
{
"name": "ゾレドロン酸水和物",
"lang": "JP"
}
]
] | null |
NCT02028923 | [
{
"id_field": "org_study_id",
"id_value": [
"IC 2013-01"
]
},
{
"id_field": "acronym",
"id_value": [
"EMGEL"
]
}
] | https://clinicaltrials.gov/study/NCT02028923 | Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds | This phase III study aims to show that topical morphine low doses treats localized pain in chronic wounds, intense and rebellious to systemic analgesics included or not opioids. | Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds | [
{
"description": "Topical",
"name": "Morphine gel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Topical",
"name": "Neutral gel",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
}
] | [
{
"design_group_description": "morphine 30 mg, quantity of gel per application: 15mg (15ml)",
"design_group_title": "Morphine gel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descript... | [
"Local Pain",
"Chronic Wounds"
] | [
"Institut Curie"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
[
{
"name": "硫酸吗啡",
"lang": "CN"
},
{
"name": "Morphine Sulfate",
"lang": "EN"
},
{
"name": "モルヒネ硫酸塩水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EMGEL"
}
] |
NCT01722240 | [
{
"id_field": "org_study_id",
"id_value": [
"1966"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01DK092653-01A1"
]
},
{
"id_field": "acronym",
"id_value": [
"1966"
]
}
] | https://clinicaltrials.gov/study/NCT01722240 | Liraglutide in Type 1 Diabetes | The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes. The investigators have, therefore, designed this study to investigate the central hypothesis that in patients with type 1 diabetes, L... | Liraglutide in Type 1 Diabetes | [
{
"name": "Liraglutide 1.8mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Daily Injection",
"design_group_title": "Liraglutide 1.8mg",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_name": "Liraglutide 1.8mg",
"interv... | [
"Type 1 Diabetes"
] | [
"State University of New York at Buffalo"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "利拉鲁肽",
"lang": "CN"
},
{
"name": "Liraglutide",
"lang": "EN"
},
{
"name": "リラグルチド（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2ea2925ddeaeaee29a85a2042a54589e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "1966"
}
] |
NCT00361582 | [
{
"id_field": "org_study_id",
"id_value": [
"CR011218"
]
}
] | https://clinicaltrials.gov/study/NCT00361582 | A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery | The purpose of this study is to evaluate in patients who are eligible for elective primary total or partial joint replacement of the hip or knee due to chronic osteoarthritis the efficacy (level of pain control) of CG5503 over 5 and 10 days compared with placebo, and to assess the safety and tolerability of multiple do... | A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease | [
{
"name": "CG5503 IR; tapentadol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Osteoarthritis",
"Pain Assessment",
"Arthralgia"
] | [
"Johnson & Johnson Pharmaceutical Research & Development LLC"
] | [
"Grünenthal GmbH"
] | [
[
{
"name": "盐酸他喷他多",
"lang": "CN"
},
{
"name": "Tapentadol Hydrochloride",
"lang": "EN"
},
{
"name": "タペンタドール塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00408356 | [
{
"id_field": "org_study_id",
"id_value": [
"2004-017"
]
}
] | https://clinicaltrials.gov/study/NCT00408356 | Immunological and Clinical Responses to Zinc in Children With Diarrhoea | Zinc deficiency has been found to be widespread among children in developing countries.Clinical and field studies have consistently observed an association between zinc deficiency and higher rates of infectious diseases, including skin infections, diarrhea, respiratory infections, malaria, and delayed wound healing. Ba... | Immunological and Clinical Responses to Zinc: A Randomized, Double-Blind Trial of Zinc Treatment vs. Zinc Treatment Plus Daily Supplementation for 3 Months Among Children Under 2 Years of Age With an Acute Diarrheal Illness. | [
{
"name": "Zinc",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Diarrhoea"
] | [
"International Centre for Diarrhoeal Disease Research, Bangladesh"
] | [
"Gates Foundation (United States)"
] | [
[
{
"name": "氧化锌",
"lang": "CN"
},
{
"name": "Zinc Oxide",
"lang": "EN"
}
]
] | null |
NCT01143064 | [
{
"id_field": "org_study_id",
"id_value": [
"BHR-100-301"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2010-018283-16"
]
},
{
"id_field": "acronym",
"id_value": [
"SyNAPSe"
]
}
] | https://clinicaltrials.gov/study/NCT01143064 | Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury | The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery. | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients With Severe Traumatic Brain Injury | [
{
"description": "Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.",
"name": "Progesterone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BHR-100"
],
"type": "Drug"
},
{
"... | [
{
"design_group_title": "Progesterone",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administe... | [
"Brain Injuries"
] | [
"BHR Pharma LLC"
] | [
"Syneos Health, Inc.",
"PRA Health Sciences, Inc."
] | [
[
{
"name": "黄体酮",
"lang": "CN"
},
{
"name": "Progesterone",
"lang": "EN"
},
{
"name": "プロゲステロン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8e4ad4222d25ea25a2dee8d2505a82d2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "SyNAPSe"
}
] |
NCT00252564 | [
{
"id_field": "org_study_id",
"id_value": [
"05-041"
]
}
] | https://clinicaltrials.gov/study/NCT00252564 | Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer | The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer. | Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer | [
{
"description": "5 mg/kg over 30 minutes on Days 1 and 15",
"name": "Bevacizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Avastin"
],
"type": "Drug"
},
{
"description": "85 mg/m2 on Days 1 and 15",
"name": "Oxaliplatin",
"normalized_typ... | [
{
"design_group_description": "(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via \"T\" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.<br/>Bevacizumab --> oxaliplatin and LV --> bolus 5-FU --> infusional 5-FU<br/>Dosing on Days 1 and 15 of each 28-day... | [
"Metastatic Colorectal Cancer"
] | [
"US Oncology Research LLC"
] | [
"Memorial Sloan Kettering Cancer Center",
"Bristol Myers Squibb Co.",
"Prologue Research International, Inc."
] | [
[
{
"name": "西妥昔单抗",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
},
{
"name": "セツキシマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "亚叶酸钙",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
{
... | null |
NCT07249632 | [
{
"id_field": "org_study_id",
"id_value": [
"RC18-C307"
]
}
] | https://clinicaltrials.gov/study/NCT07249632 | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible subjects aged 12 to 80 years with a diagnosis of OMG (Myasthenia Gravis Foundation of America [... | A Phase III Trial of Telitacicept in Patients With Ocular Myasthenia Gravis | [
{
"description": "The dosage is administered based on the subject's age and baseline body weight.",
"name": "Telitacicept",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "The placebo contains no active ingredients. To maintain the blind, the placeb... | [
{
"design_group_title": "Telitacicept",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "The dosage is administered based on the subject's age and baseline body weight.",
... | [
"Myasthenia Gravis, Ocular"
] | [
"RemeGen Co., Ltd."
] | [
"Shanghai Huashan Hospital",
"Beijing Hospital of the Ministry of Health"
] | [
[
{
"name": "泰它西普",
"lang": "CN"
},
{
"name": "Telitacicept",
"lang": "EN"
}
]
] | null |
NCT04383691 | [
{
"id_field": "org_study_id",
"id_value": [
"D1071301"
]
}
] | https://clinicaltrials.gov/study/NCT04383691 | A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression | The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression. | A Randomized, 6-Week, Multicenter, Double-Blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression | [
{
"description": "Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.",
"name": "Lurasidone HCl",
"normal... | [
{
"design_group_description": "Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.",
"design_group_title": "L... | [
"Bipolar I Depression"
] | [
"Sumitomo Pharma Co., Ltd."
] | [
"Sumitomo Pharma America, Inc."
] | [
[
{
"name": "盐酸鲁拉西酮",
"lang": "CN"
},
{
"name": "Lurasidone Hydrochloride",
"lang": "EN"
},
{
"name": "ルラシドン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT05231044 | [
{
"id_field": "org_study_id",
"id_value": [
"B21-301"
]
}
] | https://clinicaltrials.gov/study/NCT05231044 | A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp | This Phase III study is designed to evaluate the efficacy and safety of KX01 Ointment in adult participants when applied to an area of skin containing more than 1, clinically typical Actinic Keratosis (AK) lesions on the face or scalp. | A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy, Safety and PK Study of KX01 Ointment 1% in Japanese Adult Subjects With Actinic Keratosis on the Face or Scalp | [
{
"description": "The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.",
"name": "KX01 ointment 1%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Vehicle Ointment is used in participants... | [
{
"design_group_description": "KX01 Ointment 1% is applied topically once daily for 5 consecutive days on face or scalp",
"design_group_title": "KX01 Ointment 1%",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Actinic Keratosis"
] | [
"PharmaEssentia Corp."
] | [
"PharmaEssentia Japan KK"
] | [
[
{
"name": "特班布林",
"lang": "CN"
},
{
"name": "Tirbanibulin",
"lang": "EN"
}
]
] | null |
NCT00002836 | [
{
"id_field": "org_study_id",
"id_value": [
"DM95-047"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA016672"
]
},
{
"id_domain": "UT MD Anderson Cancer Center",
"id_field": "secondary_id",
"id_type": "Other Id... | https://clinicaltrials.gov/study/NCT00002836 | Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of ch... | A Phase III Randomized Comparison of High Dose Chemotherapy G-CSF To G-CSF For Mobilization of Peripheral Blood Stem Cells For Autologous Transplantation For Patients With Responsive Metastatic Breast Cancer Or High Risk Stage II-III Patients | [
{
"description": "For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.",
"name": "Filgrastim (G-CSF)",... | [
{
"design_group_title": "Filgrastim + Chemotherapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day ... | [
"Breast Cancer"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "エトポシド",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name"... | null |
NCT00688376 | [
{
"id_field": "org_study_id",
"id_value": [
"E2020-G000-333"
]
},
{
"id_domain": "NCT00687635",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"E2020-G000-334"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
... | https://clinicaltrials.gov/study/NCT00688376 | Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment | The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment. | Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment | [
{
"description": "During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg dep... | [
{
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets st... | [
"Attention Impairment"
] | [
"Eisai, Inc."
] | [
"Eisai Co., Ltd."
] | [
[
{
"name": "盐酸多奈哌齐",
"lang": "CN"
},
{
"name": "Donepezil Hydrochloride",
"lang": "EN"
},
{
"name": "ドネペジル塩酸塩",
"lang": "JP"
}
]
] | null |
NCT04098666 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAS6912"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01AG062624"
]
},
{
"id_field": "acronym",
"id_value": [
"MAP"
]
}
] | https://clinicaltrials.gov/study/NCT04098666 | Metformin in Alzheimer's Dementia Prevention | MAP will be a multisite phase II/III 1:1 randomized controlled trial (RCT) of long acting metformin (reduced mass Glucophage XR) vs. matching placebo in 326 men and women with early and late aMCI, without diabetes, not treated with metformin, overweight or obese, aged 55 years to 90 years. The RCT will last 18 months a... | Metformin in Alzheimer's Dementia Prevention | [
{
"description": "Placebo tablet identical to metformin, up to 4 tablets a day",
"name": "Placebo oral tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Placebo"
],
"type": "Drug"
},
{
"description": "Metformin extended release 500 mg tablets, up ... | [
{
"design_group_description": "Extended release metformin 500 mg tablets up to 2,000 mg (4 tablets) a day once at night. The maximum dose will be attempted during a titration period in the first month of the study.",
"design_group_title": "metformin users",
"design_group_type": "Experimental",
"desi... | [
"Mild Cognitive Impairment"
] | [
"Columbia University"
] | [
"Boston University",
"The University of Texas Southwestern Medical Center",
"State University of New York at Buffalo",
"The University of New Mexico",
"Eastern Virginia Medical School",
"Medical College of Wisconsin",
"Stanford University",
"Pennington Biomedical Research Center",
"National Institut... | [
[
{
"name": "二甲双胍",
"lang": "CN"
},
{
"name": "Metformin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MAP"
}
] |
NCT02176460 | [
{
"id_field": "org_study_id",
"id_value": [
"COL-01"
]
}
] | https://clinicaltrials.gov/study/NCT02176460 | Colchicine for Symptom and Inflammation in Knee Osteoarthritis | Uric acid may be involved in the activation of the innate immune response in osteoarthritis (OA) pathology and progression. This suggests that traditional gout therapy may be beneficial for OA. Our goal therefore is to assess colchicine, an existing commercially available agent for gout, for a new therapeutic indicatio... | A Randomized Controlled Trial of Colchicine for Symptom and Inflammation Modification in Knee Osteoarthritis | [
{
"description": "0.5mg twice daily for 16 weeks",
"name": "Colchicine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"generic colchicine tablets (SIN 12490P)"
],
"type": "Drug"
},
{
"description": "1 tablet twice daily",
"name": "Placebo",
"no... | [
{
"design_group_description": "0.5mg twice daily for 16 weeks",
"design_group_title": "colchicine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "0.5mg twice daily for 16 ... | [
"Knee Osteoarthritis"
] | [
"Singapore General Hospital Pte Ltd."
] | [
"Duke-NUS Graduate Medical School Singapore",
"Duke University"
] | [
[
{
"name": "秋水仙碱",
"lang": "CN"
},
{
"name": "Colchicine",
"lang": "EN"
},
{
"name": "コルヒチン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "de54ae25e223aa52825ee22a82eea0dd",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "COLKOA"
}
] |
NCT00524849 | [
{
"id_field": "org_study_id",
"id_value": [
"CZOL446ECN05"
]
}
] | https://clinicaltrials.gov/study/NCT00524849 | Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis | The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (VEGF) levels in breast cancer patients with bone metastases. Sixty patients will be randomized into two groups. | Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases | [
{
"description": "Zometa 1 mg weekly (intravenous)",
"name": "Zoledronic acid",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Zometa"
],
"type": "Biological"
},
{
"description": "Zometa 4 mg every four weeks (intravenous)",
"name": "Zoledronic acid... | [
{
"design_group_description": "Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.",
"design_group_title": "conventional Zometa",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"interv... | [
"Metastatic Breast Cancer",
"Bone Metastases"
] | [
"Fudan University"
] | [
"Novartis AG"
] | [
[
{
"name": "唑来膦酸",
"lang": "CN"
},
{
"name": "Zoledronic Acid",
"lang": "EN"
},
{
"name": "ゾレドロン酸水和物",
"lang": "JP"
}
]
] | null |
NCT00725270 | [
{
"id_field": "org_study_id",
"id_value": [
"SU-06012008-1191"
]
},
{
"id_field": "secondary_id",
"id_value": [
"76458"
]
}
] | https://clinicaltrials.gov/study/NCT00725270 | Treatment of Schizoaffective Disorder Using Mifepristone | This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder. | Treatment of Schizoaffective Disorder Using Mifepristone | [
{
"description": "600 mg of mifepristone",
"name": "Mifepristone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo comparator",
"name": "Placebo Oral Tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
... | [
{
"design_group_description": "Patients will be randomized to placebo",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Placebo compar... | [
"Psychotic Disorders",
"Depressive Disorder, Major",
"Depressive Disorder"
] | [
"Stanford University"
] | [
"Pritzker Family Foundation"
] | [
[
{
"name": "米非司酮",
"lang": "CN"
},
{
"name": "Mifepristone",
"lang": "EN"
},
{
"name": "ミソプロストール",
"lang": "JP"
}
]
] | null |
NCT00973349 | [
{
"id_field": "org_study_id",
"id_value": [
"V112_01"
]
}
] | https://clinicaltrials.gov/study/NCT00973349 | Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults | This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in non-elderly and elderly adults. | A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Adult Subjects 18 or More Years of Age | [
{
"description": "8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant",
"name": "MF59-eH1N1_f",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "50% of MF59 with 3.75 µg A/H1N1 antigen",
"design_group_title": "3.75_(50)MF59",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "8 arms consis... | [
"Influenza"
] | [
"Novartis AG"
] | [
"Novartis Vaccines & Diagnostics, Inc."
] | [
[
{
"name": "Influenza vaccine(Seqirus GmbH)",
"lang": "EN"
}
]
] | null |
NCT00178503 | [
{
"id_field": "org_study_id",
"id_value": [
"R01MH072263"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01MH072263"
]
},
{
"id_field": "secondary_id",
"id_value": [
"DDTR B2-NDA"
]
}
] | https://clinicaltrials.gov/study/NCT00178503 | Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children | This study examined the cognitive and behavioral differences in children who have an autism spectrum disorder (ASD) with or without additional symptoms of ADHD. The study also examined the effectiveness of a range of doses of methylphenidate in improving cognitive and behavioral outcomes in children with both ASD and A... | ADHD Symptoms in Autism: Cognition, Behavior, Treatment | [
{
"description": "Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (... | [
{
"design_group_description": "24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase",
"design_group_title": "MPH Trial-Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
... | [
"Autism",
"Attention Deficit Disorder With Hyperactivity"
] | [
"The University of Texas Health Science Center at Houston"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "盐酸哌甲酯",
"lang": "CN"
},
{
"name": "Methylphenidate Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT00291226 | [
{
"id_field": "org_study_id",
"id_value": [
"0502027440"
]
}
] | https://clinicaltrials.gov/study/NCT00291226 | Glycine vs Placebo for the Schizophrenia Prodrome | Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo. | Glycine vs Placebo for the Schizophrenia Prodrome | [
{
"description": "Glycine 0.4 g/kg bid",
"name": "Glycine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Glycine dosing was fixed at an initial dose of 0.2 g/kg q.h.s for 3 days, then 0.2 g/kg b.i.d. for 4 days, then 0.2 g/kg in the a.m. and 0.4 g/kg in the p.m. for 4 days, and finally 0.4 g/kg b.i.d. Subjects weighing > 100 kg were limited to a total daily dose of 80 g daily. Glycin... | [
"Schizophrenia Prodrome"
] | [
"Yale University"
] | [
"National Alliance for Research on Schizophrenia & Depression",
"GlyTech, Inc."
] | [
[
{
"name": "甘氨酸",
"lang": "CN"
},
{
"name": "Glycine",
"lang": "EN"
}
]
] | null |
NCT03085368 | [
{
"id_field": "org_study_id",
"id_value": [
"lapatinib"
]
}
] | https://clinicaltrials.gov/study/NCT03085368 | A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin | This is a randomized controlled trial of HER-2 positive breast cancer patients treated with lapatinib and paclitaxel vs herceptin and paclitaxel with sequential and synchronous anthracycline | A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib and Paclitaxel vs Herceptin and Paclitaxel With Sequential and Synchronous Anthracycline | [
{
"description": "Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment o... | [
{
"design_group_description": "Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: ... | [
"HER2-positive Breast Cancer"
] | [
"Peking Union Medical College Hospital"
] | [
"EOC Pharma (Thaizhou) Co., Ltd."
] | [
[
{
"name": "曲妥珠单抗",
"lang": "CN"
},
{
"name": "Trastuzumab",
"lang": "EN"
},
{
"name": "トラスツズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "二甲苯磺酸拉帕替尼",
"lang": "CN"
},
{
"name": "Lapatinib Ditosylate Hydrate",
"lang": ... | null |
NCT00684554 | [
{
"id_field": "org_study_id",
"id_value": [
"#5600"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"K23DA020000"
]
}
] | https://clinicaltrials.gov/study/NCT00684554 | Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial | The study will assess the effectiveness of at-home vs. in-office induction for patients entering buprenorphine maintenance at Associates in Internal Medicine (AIM) primary care clinic. | Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial of At-Home Versus In-Office Buprenorphine Induction | [
{
"description": "Dose is determined according to the participants' individual need.",
"name": "Buprenorphine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Bup"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Buprenorphine Unobserved at home induction",
"design_group_title": "Unobserved-at home",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "... | [
"Opioid-Related Disorders",
"Heroin Dependence"
] | [
"The New York State Psychiatric Institute"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "盐酸丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine Hydrochloride",
"lang": "EN"
},
{
"name": "ブプレノルフィン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00004795 | [
{
"id_field": "org_study_id",
"id_value": [
"199/11930"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NU-517"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NU-517;199/11930"
]
}
] | https://clinicaltrials.gov/study/NCT00004795 | Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus | OBJECTIVES: I. Evaluate the safety and efficacy of synthetic dehydroepiandrosterone (GL701) in women with prednisone-dependent systemic lupus erythematosus.<br/>II. Describe the pharmacokinetics of GL701. | null | [
{
"name": "dehydroepiandrosterone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Systemic Lupus Erythematosus"
] | [
"National Center for Research Resources"
] | [
"Northwestern University"
] | [
[
{
"name": "普拉睾酮",
"lang": "CN"
},
{
"name": "Prasterone",
"lang": "EN"
}
]
] | null |
NCT00152633 | [
{
"id_field": "org_study_id",
"id_value": [
"Retina-Losartan"
]
}
] | https://clinicaltrials.gov/study/NCT00152633 | Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension | Essential hypertension is commonly associated with impaired endothelial function. The retinal vasculature is morphologically and functionally related to the cerebral vessels because of the common origin from the internal carotid artery. A recent study in hypertensive patients demonstrated that endothelial function of t... | Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension | [
{
"name": "Losartan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Metoprolol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Treatment with Losartan",
"name": "Losartan",
"normalized_type... | [
{
"design_group_description": "Treatment with Losartan.",
"design_group_title": "Losartan",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Treatment with Losartan",
... | [
"Hypertension"
] | [
"Friedrich Alexander Universität Erlangen Nürnberg"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "酒石酸美托洛尔",
"lang": "CN"
},
{
"name": "Metoprolol Tartrate",
"lang": "EN"
},
{
"name": "メトプロロール酒石酸塩",
"lang": "JP"
}
],
[
{
"name": "氯沙坦钾",
"lang": "CN"
},
{
"name": "Losartan Potassium",
"lang": "EN"
... | null |
NCT05797831 | [
{
"id_field": "org_study_id",
"id_value": [
"KRT-232-118"
]
},
{
"id_domain": "ENGOT",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"ENGOT en-21"
]
},
{
"id_domain": "GOG Foundation",
"id_field": "secondary_id",
"id_type": "... | https://clinicaltrials.gov/study/NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy.<br/>The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin al... | A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy | [
{
"description": "Navtemadlin is an experimental MDM2 anticancer drug taken by mouth",
"name": "Navtemadlin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"KRT-232"
],
"type": "Drug"
},
{
"description": "Navtemadlin placebo is a placebo that is the sam... | [
{
"design_group_description": "Navtemadlin administered orally at 180 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.",
"design_group_title": "Part 1 Arm 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": ... | [
"Endometrial Cancer"
] | [
"Kartos Therapeutics, Inc."
] | [
"The Gynecologic Oncology Group",
"The European Network for Gynaecological Oncological Trial groups (ENGOT)"
] | [
[
{
"name": "Navtemadlin",
"lang": "EN"
}
]
] | null |
NCT00209833 | [
{
"id_field": "org_study_id",
"id_value": [
"AML 01/99 trial"
]
}
] | https://clinicaltrials.gov/study/NCT00209833 | Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | This randomized phase II/III trial investigates the antileukemic activity and toxicity of the FLAG-Ida regimen as a second induction course in patients with acute myeloid leukaemia and bad response to the first induction cycle and/or with a high risk karyotype and compares the antileukemic activity and toxicity of high... | Protocol for the Treatment of Adults Aged </= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial) | [
{
"name": "Cytarabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "Idarubicin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": ... | null | [
"De Novo Akute Myeloid Leukemia (AML)",
"Secondary Acute Myeloid Leukemia (AML)",
"Refractory Anemia With Excess of Blasts in Transformation"
] | [
"Hannover Medical School"
] | [
"Universität Ulm",
"Humboldt-Universität zu Berlin",
"Hospital of the Johann Wolfgang Goethe University",
"Universitatsklinikum Augsburg",
"Universitätsklinikum Freiburg",
"Ghent University Hospital",
"Universitätsklinikum Hamburg-Eppendorf"
] | [
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "エトポシド",
"lang": "JP"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AML 01/99 trial"
}
] |
NCT02510469 | [
{
"id_field": "org_study_id",
"id_value": [
"Ahead-G315"
]
}
] | https://clinicaltrials.gov/study/NCT02510469 | Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells | The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after adjuvant chemotherapy in progressive gastric cancer patients with positive exfoliative cancer cells. | null | [
{
"description": "Apatinib Mesylate Tablets 500 mg qd p.o.",
"name": "Apatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ATAN"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)",
"design_group_title": "Apatinib Maintenance Therapy After Adjuvant Chemotherapy",
"design_group_type": "Experimental",
"d... | [
"Gastric Cancer"
] | [
"Hebei Medical University"
] | [
"Jiangsu Hengrui Pharmaceuticals Co., Ltd."
] | [
[
{
"name": "甲磺酸阿帕替尼",
"lang": "CN"
},
{
"name": "Apatinib Mesylate",
"lang": "EN"
}
]
] | null |
NCT05033743 | [
{
"id_field": "org_study_id",
"id_value": [
"10283"
]
}
] | https://clinicaltrials.gov/study/NCT05033743 | Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study | The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks. | Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study | [
{
"description": "Once weekly 2g oral secnidazole for 18 weeks",
"name": "Secnidazole 2 GM Oral Granules",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Secnidazole treatment",
"design_group_title": "Treatment Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Once weekly 2g oral secnidazo... | [
"Recurrent Bacterial Vaginosis"
] | [
"Indiana University"
] | [
"Lupin Pharmaceuticals, Inc."
] | [
[
{
"name": "塞克硝唑",
"lang": "CN"
},
{
"name": "Secnidazole",
"lang": "EN"
}
]
] | null |
NCT00273533 | [
{
"id_field": "org_study_id",
"id_value": [
"HOE498/6007"
]
}
] | https://clinicaltrials.gov/study/NCT00273533 | Ramipril in Rheumatoid Arthritis | The present study is designed to evaluate the hypothesis that the Angiotensin-Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with Rheumatoid Arthritis. | Effects of Ramipril on Endothelial Function in Patients With Rheumatoid Arthritis | [
{
"name": "Ramipril",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Arthritis, Rheumatoid"
] | [
"University of Zurich"
] | [
"Sanofi"
] | [
[
{
"name": "雷米普利",
"lang": "CN"
},
{
"name": "Ramipril",
"lang": "EN"
}
]
] | null |
NCT04082364 | [
{
"id_field": "org_study_id",
"id_value": [
"CP-MGAH22-06"
]
},
{
"id_field": "acronym",
"id_value": [
"MAHOGANY"
]
}
] | https://clinicaltrials.gov/study/NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.<br/>Part A is a single-arm cohort (Cohort A, 40 to 110 participants) will evaluate safety and efficacy of margetuximab plus retifanlima... | A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer | [
{
"description": "margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle",
"name": "margetuximab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"MGAH22",
"Margenza®"
],
"type": "Biological"
},
{
"descripti... | [
{
"design_group_description": "margetuximab plus retifanlimab",
"design_group_title": "Chemotherapy-free arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Retifanlimab: ... | [
"Gastric Cancer",
"Gastroesophageal Junction Cancer",
"HER2-positive Gastric Cancer"
] | [
"MacroGenics, Inc."
] | [
"Zai Lab (Shanghai) Co., Ltd."
] | [
[
{
"name": "特泊利单抗",
"lang": "CN"
},
{
"name": "Tebotelimab",
"lang": "EN"
}
],
[
{
"name": "马吉妥昔单抗",
"lang": "CN"
},
{
"name": "Margetuximab",
"lang": "EN"
}
],
[
{
"name": "瑞弗利单抗",
"lang": "CN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "858e228e882824d502ee294839522d8d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a4e8ea99eed554e3994a4a8d9a855a32",
"s... |
NCT04692766 | [
{
"id_field": "org_study_id",
"id_value": [
"CL04018068"
]
}
] | https://clinicaltrials.gov/study/NCT04692766 | Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis | The goal of this study was to evaluate the Efficacy and Safety of RPH-104 Treatment in patients in comparison to placebo with Idiopathic Recurrent Pericarditis | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis | [
{
"description": "solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial",
"name": "RPH-104",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL... | [
{
"design_group_description": "subjects will receive RPH-104 at a dose of 80 mg subcutaneously once every 2 weeks",
"design_group_title": "RPH-104 80 mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Pericarditis"
] | [
"R-Pharm International LLC"
] | [
"Data Management 365",
"Center of Pharmaceutical Analytics LLC"
] | [
[
{
"name": "Goflikicept",
"lang": "EN"
}
]
] | null |
NCT00477607 | [
{
"id_field": "org_study_id",
"id_value": [
"C4697-R"
]
},
{
"id_domain": "VA RR&D",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"CDR0000546570"
]
},
{
"id_domain": "VA RR&D",
"id_field": "secondary_id",
"id_type"... | https://clinicaltrials.gov/study/NCT00477607 | Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin | RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin.<br/>PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients undergoing treatment with cisplatin. | Prevention of Cisplatin Ototoxicity With the Antioxidant Alpha-Lipoic Acid | [
{
"description": "Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.",
"name": "alpha-lipoic acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"lipoic a... | [
{
"design_group_description": "Receiving alpha-lipoic acid during cisplatin treatment.",
"design_group_title": "Arm 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Suppl... | [
"Ototoxicity",
"Unspecified Adult Solid Tumor"
] | [
"US Department of Veterans Affairs (District of Columbia)"
] | [
"Oregon Health & Science University"
] | [
[
{
"name": "硫辛酸",
"lang": "CN"
},
{
"name": "Lipoic acid",
"lang": "EN"
}
]
] | null |
NCT06697301 | [
{
"id_field": "org_study_id",
"id_value": [
"EIK1001-006"
]
},
{
"id_domain": "Merck Sharp & Dohme LLC",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"KEYNOTE-G04"
]
},
{
"id_domain": "Merck Sharp & Dohme LLC",
"id_field": "seco... | https://clinicaltrials.gov/study/NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab. | A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006) | [
{
"description": "EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.",
"name": "EIK1001",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Pembrolizumab is a PD-1 inhibitor.",
"name": "Pembrolizumab (KEYTRUDA® )",
"normalized_type": ... | [
{
"design_group_description": "Participants in this arm will receive Placebo and Standard of Care (Pembrolizumab).",
"design_group_title": "Arm 1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"... | [
"Advanced Melanoma"
] | [
"Eikon Therapeutics, Inc."
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "Resiquimod Sulfate",
"lang": "EN"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT02597478 | [
{
"id_field": "org_study_id",
"id_value": [
"2015-0137"
]
},
{
"id_domain": "NCI CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2015-02132"
]
}
] | https://clinicaltrials.gov/study/NCT02597478 | Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea | The goal of this clinical research study is to learn if fentanyl can help shortness of breath in cancer patients. Researchers also want to learn if the study drug can help to improve your physical function. | A Preliminary Study of Prophylactic Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea | [
{
"description": "Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.<br/>High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shu... | [
{
"design_group_description": "Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one... | [
"Advanced Cancers"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"INSYS Therapeutics, Inc."
] | [
[
{
"name": "芬太尼",
"lang": "CN"
},
{
"name": "Fentanyl",
"lang": "EN"
},
{
"name": "フェンタニル",
"lang": "JP"
}
]
] | null |
NCT00970944 | [
{
"id_field": "org_study_id",
"id_value": [
"H133A031713"
]
}
] | https://clinicaltrials.gov/study/NCT00970944 | Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI) | This is a controlled trial of amantadine to improve level of function following severe traumatic brain injury.<br/>The purpose of this study is:<br/>1. To determine whether amantadine hydrochloride, given in a dose of 200-400 mg, improves functional recovery from the vegetative and minimally conscious states<br/>2. To ... | A Multicenter Prospective Randomized Controlled Trial of the Effectiveness of Amantadine Hydrochloride in Promoting Recovery of Function Following Severe Traumatic Brain Injury | [
{
"description": "184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (... | [
{
"design_group_description": "100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in... | [
"Traumatic Brain Injury"
] | [
"The Community Hospital Group, Inc."
] | [
"U.S. Department of Education"
] | [
[
{
"name": "盐酸金刚烷胺",
"lang": "CN"
},
{
"name": "Amantadine Hydrochloride",
"lang": "EN"
},
{
"name": "アマンタジン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT05706454 | [
{
"id_field": "org_study_id",
"id_value": [
"RAMBAN-1"
]
}
] | https://clinicaltrials.gov/study/NCT05706454 | Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia | Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.<br/>Approximately 324 eligible subjects will be randomized in a 1:1 ratio to one of the two treatment groups.<br/>Group I: Ramatroban 75 mg tablet +... | Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multi- Centre, Adaptive Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For SARS-CoV-2 Infection | [
{
"description": "Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.<br/>Subjects will be evaluated over a study period of approximately 365 days.",
"name": "Ramatroban",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_title": "Ramatroban 75 mg tablet",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total durat... | [
"COVID-19 Pneumonia",
"COVID-19 Respiratory Infection"
] | [
"Kare Biosciences, Inc."
] | [
"BioLink Life Sciences, Inc.",
"JSS Medical Research, Inc.",
"Open Philanthropy Project LLC",
"Biomedical Advanced Research & Development Authority (Barda)"
] | [
[
{
"name": "雷马曲班",
"lang": "CN"
},
{
"name": "Ramatroban",
"lang": "EN"
},
{
"name": "ラマトロバン",
"lang": "JP"
}
]
] | null |
NCT05398484 | [
{
"id_field": "org_study_id",
"id_value": [
"22-00498"
]
}
] | https://clinicaltrials.gov/study/NCT05398484 | Psilocybin Therapy in Advanced Cancer | The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications ... | A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer | [
{
"description": "One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.",
"name": "Psilocybin 25 mgs",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "One capsule contai... | [
{
"design_group_description": "Advanced cancer participants will receive experimental medication, psilocybin (25mg). In addition to the pharmacologic intervention, participants will receive a manualized psychotherapy platform. The combination of interventions is referred to as psilocybin-assisted psychotherapy ... | [
"Advanced Cancer"
] | [
"NYU Langone Health"
] | [
"National Cancer Institute"
] | [
[
{
"name": "裸盖菇素",
"lang": "CN"
},
{
"name": "Psilocybin",
"lang": "EN"
}
]
] | null |
NCT00222235 | [
{
"id_field": "org_study_id",
"id_value": [
"R01MH059807"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01MH059807"
]
}
] | https://clinicaltrials.gov/study/NCT00222235 | Adjunctive Treatment for Decreasing Symptoms of Schizophrenia | This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia. | Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) | [
{
"name": "d-cycloserine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "glycine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": ... | null | [
"Schizophrenia",
"Schizoaffective Disorder"
] | [
"University of Maryland Baltimore"
] | [
"University of Maryland",
"University of California, Los Angeles",
"National Institute of Mental Health",
"Nathan S. Kline Institute for Psychiatric Research",
"Herzog Hospital"
] | [
[
{
"name": "环丝氨酸",
"lang": "CN"
},
{
"name": "Cycloserine",
"lang": "EN"
},
{
"name": "サイクロセリン",
"lang": "JP"
}
],
[
{
"name": "甘氨酸",
"lang": "CN"
},
{
"name": "Glycine",
"lang": "EN"
}
]
] | null |
NCT00711503 | [
{
"id_field": "org_study_id",
"id_value": [
"2007-007146-34"
]
},
{
"id_field": "secondary_id",
"id_value": [
"EudraCT 2007-007146-34"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Danish EthicalH-D-2008-060"
]
},
{
"id_field": "secondary_id"... | https://clinicaltrials.gov/study/NCT00711503 | Anti-Interleukin-1 in Diabetes Action | A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret®) on the insulin production in patients with new onset Type 1 diabetes.<br/>Kineret® is already being used in the treatment of patients suffering from rheumatoid arthritis and preclinical studies are now suggesting that it may also be us... | A Randomised Clinical Trial of the Effect of Interleukin-1 Receptor Antagonism on the Insulin Production in Patients With New Onset Type 1 Diabetes | [
{
"description": "The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection",
"name": "anakinra",
"normalized_t... | [
{
"design_group_description": "The patients are instructed to administer placebo by subcutaneous injection",
"design_group_title": "2",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"interventio... | [
"Type 1 Diabetes"
] | [
"Steno Diabetes Center A/S"
] | [
"Juvenile Diabetes Research Foundation",
"Oeresund Diabetes Academy"
] | [
[
{
"name": "安纳白介素",
"lang": "CN"
},
{
"name": "Anakinra (Amgen)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AIDA"
}
] |
NCT03570749 | [
{
"id_field": "org_study_id",
"id_value": [
"16582"
]
},
{
"id_domain": "Eli Lilly and Company",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"I4V-MC-JAHO"
]
},
{
"id_field": "acronym",
"id_value": [
"BRAVE-AA1"
]
}
... | https://clinicaltrials.gov/study/NCT03570749 | A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata | This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda. | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata | [
{
"description": "Administered orally.",
"name": "Baricitinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LY3009104"
],
"type": "Drug"
},
{
"description": "Administered orally.",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c03841372... | [
{
"design_group_description": "Participants received three placebo tablets administered orally once daily (QD). Rescue therapy with Baricitinib 2 mg or 4 mg was provided to participants who failed to achieve Severity of Alopecia Tool (SALT) ≤20 (less than or equal to 20) during the study period.",
"design_g... | [
"Alopecia Areata"
] | [
"Eli Lilly & Co."
] | [
"Incyte Corp."
] | [
[
{
"name": "巴瑞替尼",
"lang": "CN"
},
{
"name": "Baricitinib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "02e8428023052a52a8da3e855e420080",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "32488230a550522aaaede23a52250529",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT07437287 | [
{
"id_field": "org_study_id",
"id_value": [
"UC-GIG-2519"
]
},
{
"id_field": "acronym",
"id_value": [
"CROCOBIL"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UC-GIG-2519"
]
}
] | https://clinicaltrials.gov/study/NCT07437287 | Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers | The goal of this clinical trial is to etablish whether adding Mitazalimab to standard chemotherapy is more effective than standard chemotherapy alone in people with advanced bile duct cancer. It will also learn about the safety of Mitazalimab.<br/>The main questions it aims to answer are:<br/>* Does the addition of Mit... | Countering Immunotherapy Resistance With Novel Combinations in Advanced Biliary Tract Cancers | [
{
"description": "oxaliplatin 85 mg/m² intravenous infusion (IV), folinic acid 400 mg/m² IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46-hours continuous IV infusion:<br/>* every two week (14-day cycles) until disease progression on control arm<b... | [
{
"design_group_title": "Mitazalimab + mFOLFOX",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "oxaliplatin 85 mg/m² intravenous infusion (IV), folinic acid 400 mg/m² IV (or L-... | [
"Biliary Tract Cancer (BTC)"
] | [
"UNICANCER"
] | [
"Alligator Bioscience AB"
] | [
[
{
"name": "亚叶酸钙",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
{
"name": "ホリナートカルシウム",
"lang": "JP"
}
],
[
{
"name": "奥沙利铂",
"lang": "CN"
},
{
"name": "Oxaliplatin",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CROCOBIL"
}
] |
NCT03455218 | [
{
"id_field": "org_study_id",
"id_value": [
"1111115-1NO in CPB 001"
]
}
] | https://clinicaltrials.gov/study/NCT03455218 | Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation | Open heart surgery requires the use of a cardiopulmonary bypass (CPB) circuit. As blood flows across the artificial surfaces of the CPB circuit, platelets are activated and consumed. This activation results in a profound inflammatory reaction and need for transfusion. This reaction is intensified in younger, smaller pa... | Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet activation-a Single Center Pilot Study | [
{
"description": "20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass",
"name": "Nitric Oxide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"INOmax"
],
"type": "Drug"
},
{
"description": "INOmax device con... | [
{
"design_group_description": "20 ppm of Nitric Oxide delivered to the oxygenator via the INOmax device for the duration of the cardiopulmonary bypass time",
"design_group_title": "Nitric Oxide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f... | [
"Inflammation",
"Platelet Dysfunction"
] | [
"Medical College of Wisconsin"
] | [
"Versiti, Inc.",
"Keenova Therapeutics Plc"
] | [
[
{
"name": "一酸化窒素",
"lang": "CN"
},
{
"name": "Nitric oxide (inhaled)",
"lang": "EN"
}
]
] | null |
NCT03321656 | [
{
"id_field": "org_study_id",
"id_value": [
"42753"
]
}
] | https://clinicaltrials.gov/study/NCT03321656 | Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | This will be a single center, prospective, open-label, randomized, controlled trial comparing Envarsus XR® to twice-daily tacrolimus. The targeted population will be patients with end stage renal disease listed for primary solitary kidney transplant. Transplant Surgery is not part of the study. | Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | [
{
"description": "0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally",
"name": "Tacrolimus",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "0.07-0.14 mg/kg/day every morning orally",
"name": "Envarsus XR",
"normalized_typ... | [
{
"design_group_description": "0.1 - 0.2 mg/kg/day in 2 divided doses every 12 hours orally",
"design_group_title": "Tacrolimus",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_descr... | [
"End Stage Renal Disease"
] | [
"University of Kentucky"
] | [
"Veloxis Pharmaceuticals A/S"
] | [
[
{
"name": "他克莫司",
"lang": "CN"
},
{
"name": "Tacrolimus",
"lang": "EN"
},
{
"name": "タクロリムス水和物",
"lang": "JP"
}
]
] | null |
NCT02939898 | [
{
"id_field": "org_study_id",
"id_value": [
"RIOTB2015"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2015-005683-41"
]
},
{
"id_domain": "Ethics Committee",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"i... | https://clinicaltrials.gov/study/NCT02939898 | Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles | The goal of this project is to identify autocrine, paracrine and endocrine factors which are associated with intercycle variation in cyclical follicle recruitment.<br/>Patients will be monitored in a natural cycle, a stimulated cycle and a follow up. In the stimulated cycle patients will be randomized to co-treatment w... | Reducing the Impact of Ovarian Stimulation - The RIOT Project Study RIOT-B: Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles | [
{
"description": "Adjuvant therapy to recFSH during ovarian stimulation",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Lactose Monohydrate"
],
"type": "Drug"
},
{
"description": "Adjuvant therapy to recFSH during ovarian stimulation... | [
{
"design_group_description": "2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH",
"design_group_title": "Lactose Monohydrate",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": ... | [
"Infertility"
] | [
"Herlev Hospital"
] | [
"Rigshospitalet",
"Copenhagen University Hospital"
] | [
[
{
"name": "来曲唑",
"lang": "CN"
},
{
"name": "Letrozole",
"lang": "EN"
},
{
"name": "レトロゾール",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RIOT-B"
}
] |
NCT05536596 | [
{
"id_field": "org_study_id",
"id_value": [
"PISV01"
]
}
] | https://clinicaltrials.gov/study/NCT05536596 | Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy | The bilateral sagittal split osteotomy (BSSO) of the mandible is one of the most used surgical techniques to achieve a harmonious jaw relation in the context of orthognathic surgery. Nevertheless, one of its main complications is neurosensory damage to the inferior alveolar nerve, which can cause severe impact in the q... | Pharmacological Treatment on the Recovery of Neurosensory Disturbance After Bilateral Sagittal Split Osteotomy: a Randomized, Double-blind Trial | [
{
"description": "Prognathism/Retrognathism correction through surgical procedures",
"name": "Orthognathic Surgery",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"Bilateral Sagittal Split Osteotomy"
],
"type": "Procedure"
},
{
"description": "Group B w... | [
{
"design_group_description": "Groups A will receive the pharmacology treatment with 1.5 mg uridine triphosphate, 2.5 mg cytidine monophosphate and 1 mg hydroxycobalamin (Citoneurone). One capsule orally three times a day for 60 days as suggested by the manufacturer for patients with trauma - compressive periph... | [
"Retrognathism",
"Prognathism",
"Orthognathic Surgery",
"Neurosensory Disorder"
] | [
"Universitat Internacional de Catalunya"
] | [
"Universidad de los Andes (Chile)"
] | [
[
{
"name": "褪黑素",
"lang": "CN"
},
{
"name": "Melatonin",
"lang": "EN"
},
{
"name": "メラトニン",
"lang": "JP"
}
],
[
{
"name": "羟钴胺",
"lang": "CN"
},
{
"name": "Hydroxocobalamin",
"lang": "EN"
},
{
"name": ... | null |
NCT03651206 | [
{
"id_field": "org_study_id",
"id_value": [
"ENGOT-en8"
]
},
{
"id_field": "acronym",
"id_value": [
"ROCSAN"
]
}
] | https://clinicaltrials.gov/study/NCT03651206 | Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) < 10% and a poor prognosis. After initial treatment (surg... | An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy | [
{
"description": "PARP Inhibitor",
"name": "Niraparib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1",
"name": "Niraparib + TSR-042 (Dostarlimab)",
"normalized_type": "26823d77f12d... | [
{
"design_group_description": "Niraparib, 200 mg or 300 mg, daily dose",
"design_group_title": "Arm A - Niraparib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "PARP Inhi... | [
"Ovarian Carcinosarcoma",
"Endometrial Carcinosarcoma"
] | [
"Arcagy-Gineco"
] | [
"Tesaro, Inc."
] | [
[
{
"name": "甲苯磺酸尼拉帕利",
"lang": "CN"
},
{
"name": "Niraparib Tosylate",
"lang": "EN"
},
{
"name": "ニラパリブトシル酸塩水和物",
"lang": "JP"
}
],
[
{
"name": "多塔利单抗",
"lang": "CN"
},
{
"name": "Dostarlimab-gxly",
"lang": "EN"
... | [
{
"identifier_source": [
{
"code": "40e82552de83e0825a5e83a843958e8e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ROCSAN"
}
] |
NCT01101451 | [
{
"id_field": "org_study_id",
"id_value": [
"GOG-0263"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2011-02037"
]
},
{
"id_domain": "NRG Oncology",
"id_field... | https://clinicaltrials.gov/study/NCT01101451 | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery | This randomized phase III trial studies radiation therapy with chemotherapy to see how well they work compared to radiation therapy alone in treating patients with stage I-IIA cervical cancer who previously underwent surgery. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, suc... | Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) | [
{
"description": "Given IV",
"name": "Cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Abiplatin",
"Blastolem",
"Briplatin",
"CDDP",
"Cis-diammine-dichloroplatinum",
"Cis-diamminedichloridoplatinum",
"Cis-diamminedichloro P... | [
{
"design_group_description": "Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.",
"design_group_title": "Arm I (EBRT, IMRT)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Cervical Adenocarcinoma",
"Cervical Adenosquamous Carcinoma",
"Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
"Stage I Cervical Cancer AJCC v6 and v7",
"Stage IA Cervical Cancer AJCC v6 and v7",
"Stage IB Cervical Cancer AJCC v6 and v7",
"Stage IIA Cervical Cancer AJCC v7"
] | [
"The Gynecologic Oncology Group"
] | [
"National Cancer Institute"
] | [
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
]
] | null |
NCT02003794 | [
{
"id_field": "org_study_id",
"id_value": [
"IVIS 001"
]
},
{
"id_field": "acronym",
"id_value": [
"IVIS"
]
}
] | https://clinicaltrials.gov/study/NCT02003794 | Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS) | To study the result of intravenous fluid in patients with acute ischemic stroke within 72 hours. | Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS) | [
{
"description": "0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.",
"name": "0.9% NaCl solution",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Normal saline"
],
"type": "Drug"
}
] | [
{
"design_group_description": "0.9% NaCl solution infusion: 100 ml/hr for three days.",
"design_group_title": "IV Fluid",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "0.9... | [
"Ischemic Stroke"
] | [
"University of Chulalongkorn"
] | [
"National Research Council of Thailand"
] | [
[
{
"name": "氯化钠",
"lang": "CN"
},
{
"name": "Sodium Chloride",
"lang": "EN"
},
{
"name": "塩化ナトリウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "IVIS"
}
] |
NCT06994195 | [
{
"id_field": "org_study_id",
"id_value": [
"BL-B01D1-310"
]
}
] | https://clinicaltrials.gov/study/NCT06994195 | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) | This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer. | A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer | [
{
"description": "Administration by intravenous infusion for a cycle of 3 weeks.",
"name": "BL-B01D1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BMS-986507",
"iza-bren",
"izalontamab brengitecan"
],
"type": "Drug"
},
{
"description": "A... | [
{
"design_group_description": "Participants receive BL-B01D1 in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.",
"design... | [
"Epithelial Ovarian Cancer",
"Fallopian Tube Cancer",
"Primary Peritoneal Cancer"
] | [
"Sichuan Baili Pharmaceuticals Co.,Ltd"
] | [
"Baili Bio Chengdu Pharmaceutical Co. Ltd."
] | [
[
{
"name": "伦康依隆妥单抗",
"lang": "CN"
},
{
"name": "Izalontamab Brengitecan",
"lang": "EN"
}
]
] | null |
NCT02302716 | [
{
"id_field": "org_study_id",
"id_value": [
"15615"
]
},
{
"id_domain": "Eli Lilly and Company",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"I4L-MC-ABER"
]
},
{
"id_field": "acronym",
"id_value": [
"ELEMENT 5"
]
}
... | https://clinicaltrials.gov/study/NCT02302716 | A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus | The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications (OAMs). | A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study | [
{
"description": "Administered SC",
"name": "LY2963016",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Administered SC",
"name": "LANTUS®",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description... | [
{
"design_group_description": "Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will ... | [
"Diabetes Mellitus, Type 2"
] | [
"Eli Lilly & Co."
] | [
"Boehringer Ingelheim GmbH"
] | [
[
{
"name": "甘精胰岛素生物类似药(Boehringer Ingelheim)",
"lang": "CN"
},
{
"name": "Insulin Glargine(Boehringer Ingelheim)",
"lang": "EN"
},
{
"name": "インスリン グラルギン BS",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2e8222898320882d4d454a228832ad92",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "2e92deeaad4ea8e05ea284a2a2e0e848",
"s... |
NCT01131026 | [
{
"id_field": "org_study_id",
"id_value": [
"DV-09-0015"
]
}
] | https://clinicaltrials.gov/study/NCT01131026 | Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication | Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %. However, the eradication resulting from TRIOL treatment with levofloxacin is expected to be 75 % or higher. If the targe... | A Monocentric, Open-label, Efficacy and Safety Evaluation Study of the Triple Therapy of 500 mg Levofloxacin, 1000 mg Amoxicillin and 30 mg Lansoprazole on Helicobacter Pylori Eradication in 60 Patients Infected With H. Pylori | [
{
"description": "tablet, 500 mg, once a day for ten days",
"name": "Levofloxacin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Floxilevo 500 mg Tablet"
],
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"description": "tablet, 1000 mg, onc... | null | [
"Helicobacter Pylori Infection"
] | [
"Deva Holding AS"
] | [
"Erciyes Üniversitesi",
"TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti."
] | [
[
{
"name": "左氧氟沙星",
"lang": "CN"
},
{
"name": "Levofloxacin",
"lang": "EN"
},
{
"name": "レボフロキサシン水和物",
"lang": "JP"
}
],
[
{
"name": "兰索拉唑",
"lang": "CN"
},
{
"name": "Lansoprazole",
"lang": "EN"
},
{
... | null |
NCT00437684 | [
{
"id_field": "org_study_id",
"id_value": [
"Kamon 2"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NTC00437684"
]
}
] | https://clinicaltrials.gov/study/NCT00437684 | Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy | The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in HIV/HCV coinfected patients.<br/>Secondary objective is to assess if Lpv/r monotherapy during HCV-treatment is associ... | A Pilot, Open Label, Multicenter, Randomized Clinical Trial on Lopinavir/Ritonavir-Monotherapy vs Lopinavir/Ritonavir Plus Selected Nucs, in HIV/HCV Coinfected Patients With Chronic Hepatitis C or Compensated Cirrhosis, Starting Treatment With Ribavirin and Pegylated Interferon | [
{
"description": "200/50 mg 2 cpr bid monotherapy",
"name": "LPV/r",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "PEG-IFNa 2a 180 mcg/week",
"name": "PEG-IFNa 2a",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
... | [
{
"design_group_description": "LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for H... | [
"HIV Infections",
"Hepatitis C"
] | [
"Ospedale San Raffaele Srl"
] | [
"Hoffmann-La Roche, Inc.",
"Abbott Laboratories"
] | [
[
{
"name": "洛匹那韦/利托那韦",
"lang": "CN"
},
{
"name": "Lopinavir/Ritonavir",
"lang": "EN"
},
{
"name": "ロピナビル/リトナビル",
"lang": "JP"
}
],
[
{
"name": "利巴韦林",
"lang": "CN"
},
{
"name": "Ribavirin",
"lang": "EN"
},
... | null |
NCT05823311 | [
{
"id_field": "org_study_id",
"id_value": [
"2023-0175"
]
}
] | https://clinicaltrials.gov/study/NCT05823311 | Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma | Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to undergo surgery.<br/>As more effective and novel chemotherapy, targeted therapies, and imm... | A Randomized, Double-blind, Multicenter Study of Lenvatinib, Temalizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma | [
{
"description": "Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.",
"name": "Lenvatinib, tislelizumab, gemcitabine and cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Intravenous inj... | [
{
"design_group_description": "Intravenous injection: gemcitabine and cisplatin (CG)+ tislelizumab； Oral administration: lenvatinib.",
"design_group_title": "GPLET (Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704... | [
"Advanced Cholangiocarcinoma"
] | [
"The Second Affiliated Hospital Zhejiang University"
] | [
"The First Affiliated Hospital of Zhengzhou University"
] | [
[
{
"name": "替雷利珠单抗",
"lang": "CN"
},
{
"name": "Tislelizumab",
"lang": "EN"
},
{
"name": "チスレリズマブ（遺伝子組換え）（JAN）",
"lang": "JP"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
... | null |
NCT00022685 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000068842"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCLA-0009041"
]
},
{
"id_field": "secondary_id",
"id_value": [
"IM-T-hLL2-07"
]
},
{
"id_field": "secondary_id",
"id_value": [
... | https://clinicaltrials.gov/study/NCT00022685 | Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma | RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.<br/>PURPOSE: Phase III trial to determine the effectiveness of epratuzumab in treating patients who have low-grade non-Hodgkin's lymphoma that has no... | A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) | [
{
"name": "epratuzumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"single_or_multi": "single_drug",
"type": "Biological"
}
] | null | [
"Lymphoma"
] | [
"Jonsson Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "依帕珠单抗",
"lang": "CN"
},
{
"name": "Epratuzumab",
"lang": "EN"
}
]
] | null |
NCT00493974 | [
{
"id_field": "org_study_id",
"id_value": [
"0701M00621"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U10HL074424"
]
},
{
"id_field": "acronym",
"id_value": [
"LEUKO"
]
}
] | https://clinicaltrials.gov/study/NCT00493974 | Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study) | Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals. The purpose of this study is to evaluate the effectiveness of zileuton, a medication that is used to control asthma symptoms, at ... | Antileukotriene Therapy for COPD Exacerbations | [
{
"description": "Zyflo tablets, 600 mg, 4 times a day",
"name": "Zileuton",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Zyflo"
],
"type": "Drug"
},
{
"description": "Placebo 4 x daily",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "Zileuton (Zyflo, 600 mg 4 times a day)",
"design_group_title": "Zileuton",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Zyflo tablets,... | [
"Pulmonary Disease, Chronic Obstructive"
] | [
"University of Minnesota"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "齐留通",
"lang": "CN"
},
{
"name": "Zileuton",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a2e25ea22de89828d50ee8e00905d222",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "LEUKO"
}
] |
NCT04210973 | [
{
"id_field": "org_study_id",
"id_value": [
"AYPB-MDD-Ⅲ-201901"
]
},
{
"id_domain": "China National Major Project for IND",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"2018ZX09734-005"
]
}
] | https://clinicaltrials.gov/study/NCT04210973 | Comparison of Anyu Peibo With Placebo in Treatment of MDD in China | The purpose of this study is to evaluate the efficacy and safety of Anyu Peibo Capsule comparing with placebo in the treatment of Chinese Patients with Depression. | Efficacy and Safety Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Ⅲ Randomized, Double-Blind, Placebo-Paralleled, Multicenter Clinical Trial | [
{
"description": "Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper",
"name": "Anyu Peibo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo Capsule, twice per day, oral after breakfast and supper",
"name": "Placebo"... | [
{
"design_group_description": "Anyu Peibo Capsule, oral, 0.8g twice per day",
"design_group_title": "Anyu Peibo",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Anyu Peibo ... | [
"Major Depressive Disorder"
] | [
"Shanghai Mental Health Center"
] | [
"Su Zhou YiHua Biotechnology Co. LTD"
] | [
[
{
"name": "安郁沛勃胶囊",
"lang": "CN"
},
{
"name": "Anyu Peibo Capsule",
"lang": "EN"
}
]
] | null |
NCT02194595 | [
{
"id_field": "org_study_id",
"id_value": [
"14-0128-A"
]
},
{
"id_field": "acronym",
"id_value": [
"PREVAIL"
]
}
] | https://clinicaltrials.gov/study/NCT02194595 | Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) | Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a randomized contr... | Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) | [
{
"name": "Basal insulin and exenatide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Basal insulin glargine",
"Exenatide"
],
"type": "Drug"
},
{
"name": "Basal insulin only",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_nam... | [
{
"design_group_description": "Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc inje... | [
"Type 2 Diabetes"
] | [
"Mount Sinai Hospital (Canada)"
] | [
"University of Toronto",
"Canadian Institutes of Health Research"
] | [
[
{
"name": "艾塞那肽",
"lang": "CN"
},
{
"name": "Exenatide",
"lang": "EN"
},
{
"name": "エキセナチド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PREVAIL"
}
] |
NCT00217022 | [
{
"id_field": "org_study_id",
"id_value": [
"1132-03"
]
},
{
"id_domain": "AstraZeneca",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"IRUSBUEN0002"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"i... | https://clinicaltrials.gov/study/NCT00217022 | Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis | Patients will receive budesonide or placebo for the treatment of active lymphocytic colitis. This study includes stool collections, blood draws, weekly questionnaires and a sigmoidoscopy. The study hypothesis is that budesonide will be safe and effective compared with placebo for the treatment of diarrhea in lymphocyti... | A Randomized, Double-Blind, Placebo Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis | [
{
"description": "Placebo, 3 tablets daily",
"name": "Placebo",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
},
{
"description": "9 mg daily (three tablets)",
"name": "Budesonide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "9 mg daily",
"design_group_title": "Budesonide",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "9 mg daily (three tablets)",
"in... | [
"Lymphocytic Colitis",
"Diarrhea"
] | [
"Mayo Clinic"
] | [
"AstraZeneca PLC",
"National Center for Research Resources"
] | [
[
{
"name": "布地奈德",
"lang": "CN"
},
{
"name": "Budesonide",
"lang": "EN"
},
{
"name": "ブデソニド",
"lang": "JP"
}
]
] | null |
NCT00861250 | [
{
"id_field": "org_study_id",
"id_value": [
"R08096M"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2008-003936-38"
]
},
{
"id_domain": "Janssen-Cilag Ltd",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number... | https://clinicaltrials.gov/study/NCT00861250 | Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT | The primary objective of this study is to determine the rate of molecular remissions (MolR) assessed by ASO-RQ-PCR technique after induction treatment with bortezomib and dexamethasone (Vel/Dex) prior to high-dose therapy with melphalan and autologous stem cell transplantation (HDT-ASCT), and after HDT-ASCT in patients... | Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-dexamethasone (Vel/Dex) Followed by HDT With ASCT | [
{
"description": "Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT",
"name": "bortezomib + dexamethasone",
"normaliz... | [
{
"design_group_title": "Vel/Dex",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, th... | [
"Multiple Myeloma"
] | [
"Tampere University Hospital"
] | [
"Helsinki University Central Hospital",
"Janssen-Cilag Ltd.",
"Turku University Hospital",
"Oulu University Hospital"
] | [
[
{
"name": "硼替佐米",
"lang": "CN"
},
{
"name": "Bortezomib",
"lang": "EN"
},
{
"name": "ボルテゾミブ",
"lang": "JP"
}
],
[
{
"name": "地塞米松",
"lang": "CN"
},
{
"name": "Dexamethasone",
"lang": "EN"
},
{
"name":... | null |
NCT00802529 | [
{
"id_field": "org_study_id",
"id_value": [
"CRO1135"
]
}
] | https://clinicaltrials.gov/study/NCT00802529 | Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease | This trial aims to compare transtympanic steroids against the standard treatment (transtympanic gentamicin) in refractory unilateral Meniere's disease. | Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial | [
{
"description": "2 transtympanic injections at interval of two weeks.",
"name": "Methylprednisolone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "2 transtympanic injections at an interval of two weeks. If there is significant hearing loss befor... | [
{
"design_group_description": "Steroid (Methylprednisolone)",
"design_group_title": "Steroid (Methylprednisolone)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "2 transty... | [
"Meniere's Disease"
] | [
"Imperial College London"
] | [
"Imperial College Healthcare NHS Trust",
"The Medical Research Council"
] | [
[
{
"name": "甲泼尼龙",
"lang": "CN"
},
{
"name": "Methylprednisolone",
"lang": "EN"
},
{
"name": "メチルプレドニゾロン",
"lang": "JP"
}
]
] | null |
NCT01327495 | [
{
"id_field": "org_study_id",
"id_value": [
"39738"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01AG037603-01"
]
},
{
"id_field": "acronym",
"id_value": [
"PROS-2"
]
}
] | https://clinicaltrials.gov/study/NCT01327495 | PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate | The investigators will conduct a three-month, randomized, placebo-controlled trial comparing the effects of increasing doses of androgen supplementation with Testosterone (T) gel on the prostate in healthy men who are treated with acyline to block gonadal androgen production. | Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2) | [
{
"description": "Placebo acyline subcutaneous injection every 2 weeks",
"name": "placebo acyline",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"other_name": [
"placebo"
],
"type": "Other"
},
{
"description": "daily placebo testosterone gel applied transdermally x 12... | [
{
"design_group_description": "Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks",
"design_group_title": "Arm 1: Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
... | [
"Healthy"
] | [
"University of Washington"
] | [
"National Institute on Aging",
"National Institutes of Health"
] | [
[
{
"name": "睾酮",
"lang": "CN"
},
{
"name": "Testosterone",
"lang": "EN"
}
],
[
{
"name": "Acyline",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PROS-2"
}
] |
NCT02654730 | [
{
"id_field": "org_study_id",
"id_value": [
"SAFEPRIM-II"
]
},
{
"id_field": "acronym",
"id_value": [
"SAFEPRIM-II"
]
}
] | https://clinicaltrials.gov/study/NCT02654730 | Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia | The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with dihydroartemisinin-piperaquine in G6PD deficient males. | Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia | [
{
"description": "G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days",
"name": "Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient",
"normalized_... | [
{
"design_group_title": "G6PD deficient 0.25 mg/kg PQ + DHAP",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "G6PD deficient participants will be treated with dihydroartemisini... | [
"Malaria"
] | [
"London School of Hygiene & Tropical Medicine"
] | [
"The Medical Research Council"
] | [
[
{
"name": "双氢青蒿素哌喹",
"lang": "CN"
},
{
"name": "Piperaquine tetraphosphate/Artenimol",
"lang": "EN"
}
],
[
{
"name": "磷酸伯氨喹",
"lang": "CN"
},
{
"name": "Primaquine Phosphate",
"lang": "EN"
},
{
"name": "プリマキンリン酸塩",
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SAFEPRIM-II"
}
] |
NCT00414128 | [
{
"id_field": "org_study_id",
"id_value": [
"MYCYC"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Eudract: 2006-001663-33"
]
},
{
"id_field": "acronym",
"id_value": [
"MYCYC"
]
}
] | https://clinicaltrials.gov/study/NCT00414128 | Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis | The purpose of this study is to investigate whether mycophenolate mofetil is effective as treatment for new cases of ANCA associated vasculitis. | A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis. | [
{
"description": "2-3g/day for 3-6 months, in tablet, capsule or liquid form",
"name": "mycophenolate mofetil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cellcept"
],
"type": "Drug"
},
{
"description": "intravenous cyclophosphamide, 15mg/kg with do... | [
{
"design_group_description": "Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day",
"design_group_title": "mycophenolate mofetil",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Vasculitis"
] | [
"Cambridge University Hospitals NHS Foundation Trust"
] | [
"Corden Pharma Fribourg SA",
"Aspreva Pharmaceuticals Corp."
] | [
[
{
"name": "吗替麦考酚酯",
"lang": "CN"
},
{
"name": "Mycophenolate Mofetil",
"lang": "EN"
},
{
"name": "ミコフェノール酸 モフェチル",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MYCYC"
}
] |
NCT03602053 | [
{
"id_field": "org_study_id",
"id_value": [
"CVIA 066"
]
},
{
"id_field": "acronym",
"id_value": [
"ROTAVAC"
]
}
] | https://clinicaltrials.gov/study/NCT03602053 | Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia | The study is being conducted to evaluate and compare the immunogenicity of ROTAVAC® and ROTAVAC 5D 28 days after the last dose of the vaccine, when administered to infants in a three-dose schedule at 6, 10 and 14 weeks of age.<br/>The study will also assess the reactogenicity of the vaccine 7 days after each vaccinatio... | An Open-label, Randomized, Controlled, Single Centre, Phase IIb Study to Assess the Immunogenicity, Reactogenicity and Safety of Three Live Oral Rotavirus Vaccines, ROTAVAC® , ROTAVAC 5CM and Rotarix® in Healthy Zambian Infants | [
{
"description": "0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.",
"name": "ROTAVAC®",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "0.5 ml of the vaccine will be administered orally thrice at 6, 10 an... | [
{
"design_group_description": "Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5D is in liquid form.",
"design_group_title": "ROTAVAC 5D",
"design_group_... | [
"Diarrhea",
"Diarrhea Rotavirus"
] | [
"Centre For Infectious Disease Research"
] | [
"Christian Medical College & Hospital",
"Bharat Biotech International Ltd.",
"Program for Appropriate Technology in Health",
"Children's Hospital & Medical Center"
] | [
[
{
"name": "轮状病毒疫苗116E(Bharat Biotech International Ltd.)",
"lang": "CN"
},
{
"name": "Rotavirus vaccine 116E(Bharat Biotech International Ltd.)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "294aa3529a52d88d5d88e203d2522988",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ROTAVAC"
}
] |
NCT03926754 | [
{
"id_field": "org_study_id",
"id_value": [
"2016-002367-34"
]
},
{
"id_domain": "Regional Ethics Committee",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"H-16030780"
]
},
{
"id_field": "acronym",
"id_value": [
"BEAT-HF I... | https://clinicaltrials.gov/study/NCT03926754 | Beta 3 Agonist Treatment in Heart Failure-2 | Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with moderate to severe chronic heart failure (LVEF<35%, NYHA III-IV).<br/>The study is a randomized, placebo-controlled, double-blinded trial in two phases wit... | Beta 3 Agonist Treatment in Heart Failure-2 | [
{
"description": "Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.<br/>Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).",
"name": "Mirabegron",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"P... | [
{
"design_group_description": "Active treatment arm (mirabegron)",
"design_group_title": "Mirabegron",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Study A The maxim... | [
"Heart Failure With Reduced Ejection Fraction NYHA Class III-IV"
] | [
"Rigshospitalet"
] | [
"Royal North Shore Hospital",
"Hillerød Hospital",
"Herlev Hospital",
"Hvidovre University Hospital",
"Bornholms Hospital"
] | [
[
{
"name": "米拉贝隆",
"lang": "CN"
},
{
"name": "Mirabegron",
"lang": "EN"
},
{
"name": "ミラベグロン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BEAT-HF II"
}
] |
NCT01950299 | [
{
"id_field": "org_study_id",
"id_value": [
"HM20000024"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R34HL121402-01"
]
},
{
"id_field": "acronym",
"id_value": [
"VCU-ART3"
]
}
] | https://clinicaltrials.gov/study/NCT01950299 | Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) | VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days. | Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3 | [
{
"description": "Anakinra 100 mg starting immediately and then every 24 hours",
"name": "Anakinra 100 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Kineret"
],
"type": "Drug"
},
{
"description": "Anakinra 100 mg starting 12 hours after first dose... | [
{
"design_group_description": "Anakinra 100 mg daily for 14 days",
"design_group_title": "Anakinra (standard dose)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Anakinra... | [
"Acute Myocardial Infarction"
] | [
"Virginia Commonwealth University"
] | [
"National Heart, Lung & Blood Institute",
"National Institutes of Health"
] | [
[
{
"name": "安纳白介素",
"lang": "CN"
},
{
"name": "Anakinra (Amgen)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "04559582e5dd4e8902d9da55d4e9e3a0",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "32a8d288aae9a982930089e224e3a49a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.